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Oxidative stress and persistent DNA damage response can lead to cellular senescence and aging. 
The ATM kinase and p53 protein play critical roles in the DNA damage response to reactive 
oxygen species and other DNA-damaging agents. Although the majority of selenoproteins carry 
antioxidant activities, little is known about the nutritional role of selenium (Se) in aging. 
Previous studies indicated that selenoprotein H (SelH) is very sensitive to dietary Se deficiency. 
Moreover, SelH is a nuclear selenoprotein that is proposed to carry redox domains and to 
transactivate redox genes including one for glutathione biosynthesis. To determine the role of 
SelH in genome maintenance, SelH and scrambled shRNA knockdown were stably established 
in MRC-5 human diploid fibroblast or immortalized cancer cells. SelH shRNA MRC-5 cells 
showed more pronounced induction of β-galactosidase expression, autofluorescence, growth 
inhibition, and ATM pathway activation (γH2AX and phospho-ATM Ser-1981) as compared to 
scrambled shRNA cells. Interestingly, the slow proliferation in SelH shRNA MRC-5 cells was 
alleviated in the presence of ATM kinase inhibitors KU 55933 and KU 60019, by p53 shRNA 
knockdown, or by maintaining the cells in 3% O2 incubator (vs. ambient O2).  Phospho-ATM 
Ser-1981 and γH2AX induction by H2O2 treatment (20 µM) was temporally exacerbated in SelH 
shRNA but reversed in the scrambled shRNA MRC-5 cells 1-5 days after recovery. GFP-SelH 
did not relocalize to sites of oxidative DNA damage. Results from cologenic assays indicated 
that SelH shRNA HeLa cells were hypersensitive to paraquat and H2O2 but not to other 
clastogens including hydroxyurea, neocarzinostatin or camptothecin. The H2O2-induced cell 
death was attenuated in the presence of N-acetyl cysteine (NAC), a glutathione analogue, in SelH 
but not in scrambled shRNA HeLa cells.  In conclusion, SelH protects against cellular 
senescence specifically to oxidative stress through a genome maintenance pathway involving 
ATM and p53. 
While recent research has demonstrated that mice unable to express selenoproteins in epidermal 
cells or in osteo-chondroprogenitor cells showed an apparently aging phenotype characterized by 
alopecia or bone abnormality, respectively. Thus, a role of selenium, particularly at nutritional 
levels of intake, in aging is largely unknown. What is lacking is an appropriate aging model of 
dietary Se deprivation displaying many features of normal aging. Telomere attrition provokes 
DNA damage response and, subsequently, replicative senescence. Because the chromosomes of 
mice carry longer telomeres than those of humans, the proposed hypothesis is that lengthy 
telomeres preclude mice deprived of Se to display aging phenotypes and age-related disorders. 
To test this hypothesis, weanling late generation Terc-/- mice were fed a Se-deficient diet or the 
diet supplemented with selenate (0.15 ppm) throughout their life. The objectives are to elucidate 
the role of Se in reducing age-related loss of function and begin to identify the key molecular 
mediators and selenoproteins during the aging process. As evidenced by changes in metabolic 
markers (body weight, glucose intolerance, insulin resistance and bone structure) and aging 
phenotypes (gray hair, alopecia, wound healing and telomere attrition), these data strongly 
indicate health span deterioration by dietary Se deficiency in the short telomere mice. 
MicroRNAs (miRNAs) are regulators of messenger RNA stability and translation and have been 
proposed as biomarkers for a variety of diseases and physiological conditions, including aging. A 
high-throughput platform, TaqMan low density array, was used to profile more than 800 
miRNAs in plasma whose expression were validated by using individual quantitative PCR. The 
expression of a couple of miRNAs were induced both by dietary Se deprivation and aging. 
Altogether, a very interesting model of aging is established in this project by deprivation of Se 
that displays many hallmarks of human aging and can reveal the roles of Se at nutritional levels, 
in contrast with previous approaches, in which these essential roles in delaying health span 
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Chapter 1: Dietary selenium, selenoprotein, genome stability, cellular 
senescence and aging 
1.1 Introduction 
Healthy aging with minimum age-related disorders is the aspiration of our aging society. 
The average life expectancy in modern society is getting longer and longer because of the 
improvements on the knowledge of medicine and technology; however, this trend may be 
compromised when elderlies suffer from age-related disorders and live with poor quality 
of life (Westendorp, 2006). Thus, it is critical and required to understand how and why 
we age.  
Aging is a complicated process with sophisticated changes at different levels, resulting in 
age-related disorders and shortened lifespan. Currently, there are various theories of 
aging to explain this phenomenon at the level of molecule, cell, system, and evolution 
(Weinert and Timiras, 2003). Our genome constantly accumulates DNA damage and 
mutations, thus impacting on cell survival. Proliferating cells with persistent DNA 
damage may be arrested at certain stages of cell cycle permanently, which can interfere 
with the systems in the body and jeopardize the quality of life. On the other hand, 
evolution selects those phenotypes for specific habitat and behavior, which may either 
accelerate or attenuate the aging process. These changes as a whole decide the life 
expectancy of the species. Thus, securing genome stability is of fundamental importance 
for healthy aging by protecting against aging and age-related disorders. 
Available lines of scientific evidence on the protection against aging and age-related 
disorders by bioactive compounds and nutrients shed lights on possible interventional 
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strategies for healthy aging. Arising from French Paradox, the red wine phytochemical, 
resveratrol, has been shown to extend the lifespan of Saccharomyces cerevisiae through 
the activation of Sirtuins (Howitz et al., 2003; Wood et al., 2004). Additionally, 
resveratrol improves the health span and lifespan of mice on a high fat diet (Baur et al., 
2006). Moreover, vitamin C, the natural antioxidant that prevents scurvy, is known to 
counteract many aging phenotypes found in a mouse model for Werner syndrome in 
humans, suggesting a potential intervention approach for Werner syndrome patients to 
age with quality of life (Massip et al., 2010). Because the potential of dietary bioactive 
components on healthy aging is largely unknown, understanding their mechanisms of 
action during the aging process is necessary and significant. 
Selenium, a trace mineral, is of great potential to prevent aging and age-related disorders. 
Selenium exists in the cells as chemical derivatives or selenium-containing proteins at 
nutritional level. According to free radical theory of aging, reactive oxygen species  
accumulate with age (Harman, 1956, 1960). Interestingly, the majority of selenoproteins 
in humans exhibits antioxidant functions, and there are eleven selenoproteins thought to 
be associated with aging and age-related disorders (McCann and Ames, 2011). On the 
other hand, the supranutritional selenium consumption may counteract a major age-
related disorder, carcinogenesis (Ip et al., 1991; Wu et al., 2010). To protect against aging 
and age-related disorders by a nutritional intervention approach, the cell- and animal-
based studies are useful and critical to understand the functions of selenium and 
selenoproteins in health span and lifespan.    
1.2 Genome Stability 
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Genome stability is secured by DNA damage response pathways, resulting in checkpoint 
activation, senescence and apoptosis at the cellular level. In the nuclei and mitochondria, 
DNA damage is addressed by direct DNA repair, epigenetic modifications, telomere 
protection and perhaps lesion bypass. Thus, genome maintenance is important to prevent 
aging and age-related disorders. DNA damage and epigenetic alteration may generate 
gene mutations or alter the transcriptome. Telomere attrition occurs naturally after each 
round of DNA replication. Chromosome ends are looped back to from the “T-loop” 
structures that mask the otherwise signals for DNA damage response. When reaching a 
critically short level, telomeres are presented in a form reminiscent of DNA breaks, thus 
triggering a DNA damage response. Although we have well developed DNA repair 
mechanisms and epigenetic regulation to maintain genome stability, DNA damage 
accumulation, declined DNA repair, or both occur on the genome as we age, resulting in 
aging and age-related disorders.  
1.2.1 DNA Damages and DNA Repair Mechanisms 
DNA repair mechanisms are required to secure genome stability for maintenance of 
normal cellular functions, but they are challenged by various endogenous and exogenous 
DNA damaging agents, including oxidative stress, UV light, carcinogens and mutagens, 
and ionized irradiation. By estimation, there are about 105 events of DNA damage 
generated per cell per day (Ciccia and Elledge, 2010), most of which, however, are 
corrected by the various DNA repair pathways. Oxidized bases, single strand breaks and 
pyrimidine dimers are repaired by base excision repair (BER) or nucleotide excision 
repair (NER), mismatched bases are repaired by mismatch repair (MMR), and interstrand 
crosslinks and doubled strand breaks are repaired by homologous recombination (HR) or 
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non-homologous end-join (NHEJ). When there are DNA damage accumulation or 
declined DNA repair activities, unrepaired DNA damage sets the stage for genome 
instability and cellular aging. 
Genome instability through continuous accumulation of unrepaired DNA damage is 
linked to aging and age-related disorders; however, the underlying mechanism is largely 
unknown. In particular, the linkage between genome maintenance and antioxidant 
nutrients such as selenium is not well studied. According to the free radical theory of 
aging, reactive oxygen species (ROS) mainly accumulated and produced through 
respiratory chain reaction in mitochondria are thought to be causative with age. The 
increased oxidative stress may generate base oxidation, DNA single and double strand 
breaks (Halliwell and Aruoma, 1991). Indeed, oxidative DNA damage has been found to 
be accumulated with age (Sohal et al., 1994). Noteworthy, animals with higher level of 
oxidative stress produced from their mitochondria have shorter maximum lifespan (Sohal 
and Brunk, 1992). Moreover, as one of the major age-related disorders, cancer at 
precancerous stage is thought to be susceptible to oxidative stress and accumulate 
unrepaired DNA damage to a point when significant mutations are formed that drive the 
transition from precancerous to malignant cells (Stratton et al., 2009). Eventually, 
malignant cells carry severely mutated and unstable genome and are resistant to oxidative 
stress, DNA damage and cell death (Cairns et al., 2011).   
In order to maintain genome stability, mammalian cells are evolved to repair various 
types of damage through BER, NER, MMR, HR and NHEJ. Defective DNA repair is the 
etiology of some progeroid syndromes, which are characterized by early onset of aging 
and age-related disorders with shortened lifespan. The hallmark progeroid syndromes is 
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Werner syndrome; others include Bloom syndrome, Cockayne syndrome, Rothmund-
Thomson syndrome, ataxia-telangiectasia, Nijmegen breakage syndrome, xeroderma 
pigmentosum and trichothiodystrophy. As aging is the accumulative phenotypes of 
various genomic, physiological and pathophysiological declines, none of the progeroid 
syndromes fully mimic normal aging, although they share various degree of similarities. 
For example, both ataxia-telangiestasia and Nijmegen breakage syndrome show 
immunodeficiency, genome instability, clinical radiosensitivity and cancer predisposition 
(Shiloh, 1997), and Werner syndrome and Nijmegen breakage syndrome both show 
graying of hair, short stature, a "bird-like" face, increased cancer susceptibility and 
reduced lifespan (reviewed in (Cheng et al., 2004)). In particular, the five members of the 
RecQ family of DNA helicases in humans seem to play a key role in the maintenance of 
general DNA metabolism including damage response, repair and replication. Werner 
syndrome, Bloom syndrome and Rothmund-Thomson syndrome are caused by mutations 
in the specific RecQ helicases (Bohr, 2008). Xeroderma pigmentosum, Cockayne 
syndrome and trichothiodystrophy are caused by defective NER (de Boer and 
Hoeijmakers, 2000). On the other hand, lack of general DNA repair capacity was found 
in older individuals and age-related disorders. Primary hepatocytes isolated from old rats 
are more sensitive to oxidative stress induced DNA damage than those from younger rats, 
owing to declined DNA repair activities in the old hepatocytes (Kennah et al., 1985). In 
human samples, the capacity of DNA DSB repair progressively decreases during the 
aging process (Garm et al., 2013). Additionally, the patients with Alzheimer's disease, 
Parkinson's disease and stroke are found to be defective in the repair of acute oxidative 
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damages in the neurons (Canugovi et al., 2013). Altogether, declined DNA repair 
contributes to aging and age-related disorders through increased genome instability.  
1.2.2 Epigenetic regulation 
Epigenetic modifications regulate the conformation and function of chromosomes. In the 
genome, DNA double helix is wrapped with histones to form nucleosome, which in turn 
is assembled to the more compact chromatin. The 23 pairs of chromosomes are observed 
only in the mitotic phase of cell cycle when chromatin fibers are further packed. The 
degree of compactness determines whether a gene can be expressed or not on the 
chromatin. The relaxed form of chromatin is known as euchromatin, which is accessible  
for transcriptional machinery to act on RNA transcription. On the other hand, DNA in 
heterochromatin is buried inside and inactive for RNA transcription. Therefore, 
chromatin conformation can regulate gene expression in an epigenetic manner. Histone 
modifications, known as histone codes, represent another key event of epigenetic 
regulation of gene expression. Known histone codes that can relax chromatin structure 
include lysine 4 methylation, lysine 9 acetylation and lysine 14 acetylation on histone 3 
and lysine 9 acetylation and arginine 3 methylation on histone 4. On the contrary, histone 
codes that promote chromatin condensation include histone 4 lysine 12 acetylation and 
histone 3 lysine 9 methylation (Jenuwein and Allis, 2001). The histone codes are 
modified by antagonistic enzymes for chromatin relaxation and condensation. Histone 
acetylation status is antagonistically regulated by histone acetyltransferase and histone 
deacetylase (Lee and Workman, 2007; Thiagalingam et al., 2003), and methylation by 
histone methyltransferase and histone demethylase (Lam et al., 2005). These epigenetic 
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events determine the compactness of the local chromatin that physically regulates the 
accessibility of transcription factors. 
Chromosome structural changes play a pivotal role in the pathogenesis of aging and age-
related disorders. In certain types of human diploid cells, pRb pathway activates cellular 
senescence and promotes the formation of heterochromatin foci (Kosar et al., 2011; 
Narita et al., 2003). Interestingly, chromatin relaxation in the nucleus helps DNA DSB 
repair to maintain genome stability (Krishnan et al., 2011). However, a recent publication 
indicates that maintaining heterochromatin in aging genes can attenuate the aging process 
(Rando and Chang, 2012). At ribosomal DNA (rDNA) loci, the heterochromatin 
formation promotes the extension of longevity in Drosophila (Larson et al., 2012). 
Additionally, histone 3 lysine 4 trimethylation modifiers, ASH-2, WDR-5, or SET-2, 
control euchromatin formation. When these modifiers are knocked down in C. elegans, 
the worms live longer due largely to the formation of heterochromatin (Greer et al., 2011). 
Nonetheless, the optimal chromatin conformation in favor of longevity remains unknown. 
The next big question in this area is to answer whether the chromatin conformation 
change in the aging genome is locus specific or stage specific. With that being elucidated, 
we will begin to develop knowledge-based intervention approaches to delay the onset of  
aging and age-related disorders.  
DNA methylation is another key event of epigenetic modifications. DNA methylation 
event modifies on the cytosine of the CpG dinucleotide, and is involved in the regulation 
of gene expression and genome maintenance (Ehrlich, 2002). About 57~71 % of human 
genomes contain methylation at CpG dinucleotide (Cooper, 1983). Among all CpG 
dinucleotides in the genome, the methylation at CpG islands is critical to regulate gene 
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expression. CpG island is a cluster of CpG dinucleotide in or near the promoter regions or 
the exon 1 of the gene (Robertson and Wolffe, 2000), and there are about 45000 CpG 
islands known to exist in humans (Antequera and Bird, 1993). Over half of the CpG 
islands are hypomethylated at active promoter region, but hypermethylated CpG 
dinucleotide around the promoter region inhibits gene transcription (Toth et al., 1989). In 
some cases of cancer, the promoter regions of the tumor suppressor genes are 
hypermethylated, supporting the development of tumorigenesis (Jones and Laird, 1999). 
For genome defense, defective DNA methylation promotes DNA deletion in DNA 
methyltransferase knockout mice (Chen et al., 1998). The evidence that supports the 
hypothesis of CpG suppression on evolution is provided by Cooper et al., from which 
methylated CpG dinucleotide is proposed to stabilize genome stability (Cooper and 
Krawczak, 1989). Results from human lung cancer deep sequencing analyses have 
showed that DNA hypomethylation is specific on repetitive sequences (short and long 
interspersed nuclear elements and long terminal repeats), segmental duplications, and 
subtelomeric regions (Rauch et al., 2008). Thus, DNA methylation is of fundamental and 
physiological significance to maintain genome stability and to regulate the expression of 
oncogenes and tumor suppressor genes. 
1.2.3 Telomere Maintenance 
Telomere length is one of the determinants of lifespan. Telomere is composed of the 
TTAGGG repetitive sequence at the very end of chromosome (Henderson and Blackburn, 
1989). In somatic cells, the length of telomere decreases after each round of cell division 
because of the natural defect in DNA replication (Greider, 1996). Telomeres lose about 
55bp after each cell doubling, and telomere attrition occurs in mortal cells both in vitro 
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and in vivo (Aviv et al., 2001; Harley et al., 1990). When the length of telomere was 
shortened to the critical threshold, such dysfunctional telomere invokes DNA damage 
response, dampens chromosome stability and limits cell viability (Hemann et al., 2001). 
DNA damage response and repair at chromosome ends with short telomeres are abnormal, 
and can result in chromosome end-to-end joining through the NHEJ pathway of DNA 
DSB repair. Despite of increasing genome instability, expressing telomerase in mortal 
cells can rescue the cells and bypass the restriction on senescence (Greider, 1998).  
Shelterin is required to structurally and functionally protect telomeres. Shelterin is 
composed of six proteins: TRF1, TRF2, TPP1, POT1, TIN2 and Rap1. TRF1, TRF2 and 
POT1 recognize and bind to TTAGGG repeats. TIN2, TPP1 and Rap1 do not directly 
bind to TTAGGG repeats, but appear at telomeres by association with TRF1, TRF2 
and/or POT1 (Palm and de Lange, 2008). There are two specialized structures at 
telomeres, telomeric-loop (T-loop) and displacement-loop (D-loop), which are stabilized 
by shelterin. At the very end of chromosome, the duplex-repeat of telomeres bends and 
forms the T-loop, where shelterin binds to the duplex-repeat for stabilizing the structure. 
Then, POT1 unwinds a part of the duplex repeat by binding to single strand TTAGGG 
repeat, enabling the 3' overhang of telomeres to invade the duplex repeat of telomere. 
This 3' overhang containing structure is called D-loop, which is required to protect 
telomere ends from being recognized as DNA damage (de Lange, 2004; Griffith et al., 
1999). Without the protection of shelterin, the uncapped telomere can be recognized as a 
form of DNA damage and provokes chromosome end-to-end fusion (Celli and de Lange, 
2005). Loss of functional TRF2 or POT1 exposes telomere ends and induces DNA 
damage response through the ataxia telangiectasia mutated (ATM) or ataxia 
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telangiectasia mutated rad3 related (ATR) pathway activation (Denchi and de Lange, 
2007; van Steensel et al., 1998). On the other hand, TRF1 is a negative regulator of 
telomere integrity as it inhibits the elongation of telomere (van Steensel and de Lange, 
1997).  
1.3 Cellular Senescence 
Cellular senescence is a permanent withdraw from cell cycle that completely stop cellular 
proliferation. Cells complete a cell division cycle through G0/G1, S, and G2/M phases. 
Single cell organism maintains normal cell cycle in order to keep propagate. Furthermore, 
cellular proliferation helps to renew or replenish cells in organs and tissues for optimal 
functions in multicellular organisms. When cells encounter specific stress inducers, 
transient cell cycle arrest is activated to allow time for recover, followed by re-entry into 
normal cell cycle if the damage is fixed. However, if the damage is too severe to repair, 
the cell cycle arrests permanently, resulting in cellular senescence.  
Cellular senescence appears to be a double-edged sword concerning optimal health. 
Because cellular senescence arrests cell cycle permanently, this is a potential strategy for 
anti-cancer or old tissue regeneration. Nevertheless, cellular senescence contributes to 
organismal aging. Hence, understanding how cellular senescence is regulated might shed 
lights on cancer or aging interventions. Here, the focus is on the causes and features of 
cellular senescence, and to discuss the molecular regulation of cellular senescence driven 
by DNA damage response and the key effecter protein, p53.  
1.3.1 The activation of cellular senescence 
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Cellular senescence can be induced by unrepaired DNA damage, dysfunctional telomere, 
acute chromosome conformation change, and mitogenic inducers. Broadly speaking, 
there are two types of senescence: telomere-dependent replicative senescence and stress-
induced senescence. The molecular mechanisms of cellular senescence are not fully 
understood, but several inducers have been reported. First, persistent DNA damage 
response (DDR) including unrepaired DNA damage or dysfunctional telomere can 
activate downstream mediators, resulting in cellular senescence. Second, the acute 
changes in chromosome structures, such as a switch from heterochromatin to 
euchromatin, can lead to cellular senescence through DDR activation in the process of 
chromosome structure relaxation (Ziv et al., 2006). Finally, mitogenic stimuli can 
promote proliferation at the expense of collapsed replication forks or misfired 
replications that activate DDR. 
1.3.1.1 Dysfunctional telomere and persistent DNA damage responses induced cellular 
senescence 
DNA damage compromises genome integrity. Our genome takes charge all the 
functions from cells to the whole body level. Unfortunately, there are various 
endogenous sources of DNA damage. Formation of endogenous DNA damage is 
inevitable as the errors can be generated during normal metabolism. By estimation, 
there are about 20,000 events of endogenous DNA damage per cell per day (Ciccia 
and Elledge, 2010). ROS, the most common inducer of endogenous DNA damage, 
are generated through respiratory chain reaction in mitochondria and during many 
immune responses. Oxidative stress can induce DNA damage, such as oxidized 
guanine, DNA single strand breaks (SSB) and DNA DSB (Breen and Murphy, 1995). 
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Another source of endogenous damage contributes to genome instability is the so-
called “end-of-replication” problem. Because the very end of lagging strand DNA 
cannot be replicated by DNA polymerase during each round of DNA duplication, 
telomere length becomes shorter and shorter. Although telomeric repeats (TTAGGG) 
are lengthy (Greider, 1996), cell regeneration and propagation continuously fire DNA 
replication, resulting in telomere shortening progressively. When telomere attrition 
reaches a very short stage, telomeric T-loop cannot be formed and the otherwise 
being protected 3’ tail exposed, a universal signal that triggers DNA damage response 
(Hemann et al., 2001; Morrish and Greider, 2009; Verdun and Karlseder, 2006).  
Acute DNA damage is usually induced by exogenous clastogens, including ionizing 
irradiation, UV light, mutagens, and carcinogens. UV irradiation from sunlight 
exposure is the most common form of clastogen that generates about 105 events of 
DNA damage per cell per day (Ciccia and Elledge, 2010). Although most of the UV-
induced DNA damage can be faithfully repaired, the same is not true for some other 
clastogens such as DSB or DNA crosslinks. Different from endogenous DNA damage, 
DNA breaks from exogenous clastogens are usually induced in a prompt manner. 
Nonetheless, if left unrepaired, both endogenous and exogenous DNA damage 
accumulate and gradually compromise genome integrity. 
DNA damage response, including checkpoint activation, DNA repair, senescence and 
apoptosis, collectively maintains genome stability and determine the fate of the cells. 
In general, checkpoint activation allows time for DNA repair machinery to fix the 
lesion. If the DNA damage is too severe or the DNA repair capability is compromised, 
unrepaired DNA damage signals the cell to go to senescence or apoptosis. Depending 
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on the types of damage, they are addressed by different pathways of DNA repair. 
BER corrects mutated bases generated by depurination, deamination, or oxidation 
through short patch or long patch sub-pathways (Frosina et al., 1996). NER fixes 
bulky helix distortions of DNA by two pathways, global genome NER or 
transcription-coupled NER (de Laat et al., 1999). MMR is a post-replication pathway 
that removes mis-incorporated bases or mutated base and matches with a correct one  
(Modrich, 1997). DNA DSB are primarily repaired by HR and NHEJ. HR requires 
end-processing of the broken ends to generate a 3’ single-stranded tail in search for 
homologous sister chromatid, resulting in error-free repair of DNA DSB. NHEJ is 
considered an error-prone repair of DNA DSBs because it simply ligates two broken 
ends together. In addition to the many proteins that execute the four major DNA 
repair pathways, the genome is protected by the shelterin that protects chromosome 
ends from being recognized as DNA breaks as detailed in Section 1.2.3. In particular, 
telomere elongation needs ATR and ATM protein kinases to activate HR for 
completion of telomere elongation, but the unprotected telomere activates persistent 
DNA damage instead of transient DNA damage response (Verdun and Karlseder, 
2006). The genome stability is thus maintained tightly by DNA damage repair 
mechanisms and by telomere stability machinery to prevent detrimental DNA damage 
accumulation. 
Persistent DNA DSBs and dysfunctional telomeres are the most pronounced inducers 
of cellular senescence (Fumagalli et al., 2012; Mallette and Ferbeyre, 2007). In the 
events of persistent DNA DSBs and dysfunctional telomeres, the ATM kinase serves 
as the major mediator that senses and transmits the signal of DNA damage to 
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downstream DNA repair and checkpoint proteins. p53 is one of the major ATM 
substrates that contribute to a senescence response. Activated ATM phosphorylates 
p53 for proliferation arrest through the activation of p21, a gate keeper protein that 
controls the G1-S transition. In addition to p53, p16INK4-Rb is another pathway that 
contributes to G1 arrest and cellular senescence in the response to DNA damage 
(Robles and Adami, 1998). Furthermore, the p16INK4-Rb pathway is proposed as the 
second barrier to reinforce the growth arrest by p53 when telomere is dysfunctional 
(Beausejour et al., 2003).   
1.3.1.2 Acute chromosome conformation changes activate cellular senescence through 
the regulation of the effectors in senescence pathways.  
Histone deacetylase inhibitor drives acute changes on chromosome structures and 
activates cellular senescence. Histone acetyltransferase (HAT) and histone 
deacetylase (HDAC) are regulators that relax and pack the structure of chromosome 
(Luo and Dean, 1999). Decreased flexibility to pack chromosome in the presence of 
HDAC inhibitors can increase heterochromatin perturbation, which is known to 
induce senescence in human diploid fibroblasts (Ogryzko et al., 1996).  
HDAC inhibitor activates p16- or p53-dependent senescence pathway through the 
increase of heterochromatin perturbation and DDR. When heterochromatin 
perturbation happens, DDR is activated together with increased ATM 
phosphorylation and γH2AX formation (Di Micco et al., 2011).  In human fibroblasts, 
HDAC inhibitors such as sodium butyrate and trichostatin can activate p16INK4-Rb 
pathway and induce cellular senescence, and this pathway does not solely depends on 
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p53 (Munro et al., 2004; Ogryzko et al., 1996). Although p53 is known as a substrate 
of SIRT1, a histone deacetylase (Kim et al., 2007), the role of p53 in cellular 
senescence induced by HDAT is not clear. It may depend upon species or cell types 
(Di Bernardo et al., 2009; Munro et al., 2004). On the other hand, p16 expression can 
be induced by inhibition of HDAC. HDAC can suppress p16 transcription through its 
recruitment to the promoter region of p16 (Zhou et al., 2009). Thus, HDAC inhibitors 
can initiate a senescence response by the induction of chromosome perturbation, 
which in turn activates DNA damage response and the p16INK4-Rb pathway.  
1.3.1.3 The mitogenic stimuli activate cellular senescence 
Mitogenic stimuli are key contributors of cell proliferation, but they may also lead to 
cellular senescence. During cell proliferation, mitogenic stimuli are required to 
activate 1) cell growth by inducing DNA replication, 2) cell division in confluent 
cultured cells, 3) several rounds of cell division in sparse cultured cells, and 4) single 
cell proliferation to monolayer population. In order to control the proliferation in 
various cell types, mitogenic stimuli function in a cell type specific manner 
(Gospodarowicz and Moran, 1976). Just like senescence, mitogenic stimulation is a 
double-edged sword, because mitogens can promote both cell proliferation and 
tumorigenesis. Interestingly, some of the mitogenic stimuli also activate cellular 
senescence. For example, tumor necrosis factor-alpha, a proinflammatory cytokine, 
not only promote proliferation by the activation of activator protein-1 (Aggarwal et 
al., 2011) but also induce cellular senescence in endothelial progenitor cells under 
chronic exposure through activation of the p38 mitogen-activated protein kinase 
(MAPK) pathway (Zhang et al., 2009). Furthermore, angiotensin II induces cell 
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proliferation by induction of DNA synthesis in certain cell types, but it can also 
induce cellular senescence in endothelial cells through the activation of MAPK 
pathway (Shan et al., 2008). The other critical mitogenic stimulus is oncogene. When 
oncogenes, such as Ras, Raf, BRAFE600, and STAT5A, are constitutively expressed in 
normal cells, cellular senescence can be induced (Mallette et al., 2007; Michaloglou 
et al., 2005; Serrano et al., 1997; Zhu et al., 1998). Under the condition of constitutive 
activation of Ras, Raf, or BRAFE600, the activated MAPK pathway leads to p53 and 
p16INK4 accumulation that induces cellular senescence. Additionally, when 
senescence is induced by the oncogenic Ras, the MAPK downstream component, 
MEK, is found to be required for the activation of cellular senescence. Furthermore, 
constitutively activated MEK alone also activate cellular senescence in primary 
murine fibroblast (Lin et al., 1998). Another pathway capable of mediating oncogene-
induced cellular senescence is DDR. Oncogenic stimuli can trigger DNA hyper-
replication, which increases DNA damages and then elicits DNA damage checkpoint 
activation, DDR, and the expression of p53 and p16INK4 (Bartkova et al., 2006; Di 
Micco et al., 2006; Mallette et al., 2007). Thus, the mitogenic stimuli in cells are 
tightly regulated by complicated signal transduction pathways in an attempt to 
prevent the transformation to malignant stage by induction of cellular senescence.    
1.3.2 The markers of cellular senescence 
Specific phenotypes of cellular senescence have been observed in vivo and in vitro. The 
phenomenon of cellular senescence was first reported by Hayflick and co-authors who 
found that the human diploid fibroblast divides at a declined rate after certain passages, 
followed by complete stop of cell proliferation when cultured in vitro (Hayflick and 
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Moorhead, 1961). Based on this finding, ceased proliferation is one of the phenotypes in 
senescent cells; however, they did not distinguish senescent from quiescent cells. 
Currently, six major senescent phenotypes are known to exist: expression of senescence-
associated beta-galactosidase (SA-β-gal), persistent DNA damage response (DDR) or 
DNA segments with chromatin alterations reinforcing senescence (DNA-SCARS), 
increased p16INK4 expression, senescence-associated heterochromatin formation (SAHF), 
transformation into senescence associated secretary phenotype, and decreased Lamin B1 
expression. These features are also observed in senescent cells in mammalian tissues. 
1.3.2.1 Senescence-associated beta-galactosidase 
SA-β-gal expression is a specific senescence marker in vitro and in vivo. Beta-
galactosidase is an abundant lysosomal enzyme with an optimal pH at 4 in young or 
immortal cells. However, SA-β-gal is activated at pH 6. The expression of SA-β-gal 
is highly correlated with cellular age in cultured cell or in tissues, and in various 
animal species (Dimri et al., 1995; van der Loo et al., 1998).   
1.3.2.2 Persistent DNA damage response (DDR)/DNA segments with chromatin 
alterations reinforcing senescence (DNA-SCARS) 
Persistent DNA damage response is present in senescent cells. DNA damage response 
includes DNA repair, checkpoint activation, damage tolerance/lesion bypass, 
apoptosis, autophagy and senescence. To maintain genome integrity, functional DDR 
at the minimum requires DNA repair proteins and DNA damage sensing proteins. In 
senescent cells, DNA damage is not appropriately or completely repaired, resulting in 
persistent DNA damage that remains for days to months. Markers of DDR include 
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those that appear rapidly at the proximity of the lesion, such as ATM activation and 
the phosphorylation of its downstream substrates (Giglia-Mari et al., 2010). Senescent 
cells continue to assemble DNA damage sensing proteins at the site of unrepaired 
DNA damage, including γH2AX, pATM on Ser-1981, or ATM/ATR substrates in the 
case of DNA breaks (Fumagalli et al., 2012; Rodier et al., 2009). In the liver of old 
Terc-/- mouse, persistent γH2AX foci overlap with senescence-associated beta-
galactosidase expression (Wang et al., 2009).  
DNA-SCARS is a form of permanent DNA damage that is associated with deficiency 
in DNA repair protein and can induce cellular senescence (Rodier et al., 2011). 
Interestingly, dysfunctional telomeres induce replicative senescence by permanently 
activating the response to DNA-SCARS. Telomere attrition to a critically short level 
results in loss of protection by shelterin and the resultant dysfunction telomeres. 
Without the protection of TRF2, dysfunction telomeres are recognized and marked by 
DNA DSB repair machinery, resulting in persistent DNA damage foci (Takai et al., 
2003). Specifically, ATM transduces DNA damage signals to downstream checkpoint 
kinase CHK2, which in turn activates p53 and p21 for senescence induction. 
Noticeably, this is distinct from another senescence pathway activated by p16INK4-
pRb (d'Adda di Fagagna et al., 2003; Herbig et al., 2004). Therefore, dysfunctional 
telomeres can provoke genome instability and the subsequent cellular senescence by 
formation of DNA-SCARS.  
1.3.2.3 Increasing p16INK4 expression  
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p16INK4 promotes cellular senescence by maintaining retinoblastoma (Rb) at 
hypophosphorylation status through inhibition of cyclin-dependent kinases. In human 
genome, there are two proteins encoded from the INK4/ARF locus on chromosome 9 
by alternative splicing, resulting in p16INK4 and p19ARF expression. These two 
products play important roles in cell cycle regulation and senescence induction. 
p19ARF mediates the p53 pathway, whereas p16INK4 regulates the pRb pathway 
(Alcorta et al., 1996; Duan et al., 2001; Sharpless and DePinho, 1999). p16INK4 was 
first identified as an inhibitor of CDK4 and CDK6 interactions with cyclin D, 
resulting in the inhibition of the kinase activities and cell proliferation (Guan et al., 
1994; Serrano et al., 1993). To induce cellular senescence, p16INK4 requires pRb to 
arrest cell cycle at G1 phase (Lukas et al., 1995) and helps to maintain the 
hypophosphorylated form of pRb, the active and stabilized pRB (Ezhevsky et al., 
1997). The cooperation between p16INK4 and pRb promotes cellular senescence when 
cells encounter persistent DNA damage or mitogenic signals (Shapiro et al., 1998; 
Takahashi et al., 2006). 
p16INK4 is one of the markers of cellular senescence in vitro or in vivo, and a key gate 
keeper controlling the transition from proliferating to senescent cells (Reznikoff et al., 
1996). Because the turnover rate of p16INK4 mRNA is greater in senescent than 
proliferating cells in vitro, p16INK4 mRNA can also serve as an indicator of cellular 
senescence (Kim et al., 2002a; Wang et al., 2005). Nonetheless, both p16INK4 mRNA 
and protein levels are ideal senescence markers in vivo (Liu et al., 2009; Ohtani et al., 
2010; Ressler et al., 2006). 
1.3.2.4 Senescence-associated heterochromatin formation 
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Senescence-associated heterochromatin foci (SAHF) are structurally different from 
regular heterochromatin and can be induced during the process of cellular senescence. 
The first observation of SAHF is observed in senescent human diploid fibroblast cells 
(Narita et al., 2003). Like other forms of heterochromatin, SAHF formation is 
accompanied with the expression of K9M-H3 (histone H3 methylated on Lysine 9) 
and HP1 in the pericentric regions. However, SAHF distinctly accumulate 
phosphorylated HP1γ and HMGA (High-mobility group A) proteins in a manner 
requiring HIRA, ASF1, and macroH2A (Narita et al., 2006; Zhang et al., 2007). 
Another distinctive feature of SAHF is the loss of histone H1, which can be explained 
by the observation that HMGA protein is a stronger competitor than histone H1 in 
binding linker DNA in senescent cells (Funayama et al., 2006). SAHF can also be  
formed by the induction of mitogenic stimuli. This chromatin conformation change 
needs the p16INK4-pRB pathway activation to inhibit the function of E2F; interestingly, 
the binding of pRb to some of the E2F responsive genes is critical for 
heterochromatin formation and gene silencing (Narita et al., 2003). Additionally, 
inhibition of the Wnt signaling pathway leads to cellular senescence and SAHF 
formation in a manner independent of p53 or pRb (Ye et al., 2007). In summary, 
chromosome reorganization and the formation of SAHF are guided by pathways 
involved in cellular senescence but not proliferation. 
The formation of SAHF in senescence cells depends upon cell types and stimuli. 
MRC-5 and BJ human normal fibroblasts and primary keratinocytes form SAHF 
under oncogenic stimulation. However, only MRC-5 cells can form SAHF under 
etoposide, doxorubicin, hydroxyurea, bacterial intoxication and telomere attrition 
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(Kosar et al., 2011). These findings raised additional questions regarding the 
mechanism of SAHF formation and how to appropriately use SAHF as a senescence 
marker. Although SAHF do not universally appear in all cell types and oncogenic 
stimuli, the formation of SAHF is useful to distinguish senescent from proliferative or 
quiescent cells (Narita et al., 2003). 
1.3.2.5 Transforming into senescence-associated secretary phenotype 
Senescence-associated secretary phenotype (SASP) controls the senescence 
microenvironment through non-autonomous regulation. SASP was first found in cells 
with oncogene-induced senescence (Kuilman et al., 2008), displaying persistent DDR 
and increased chemokine and cytokine secretion. On the contrary, knockdown of a 
chemokine receptor CXCR2 alleviates replicative and oncogene-induced senescence 
and decreases DDR (Acosta et al., 2008a; Kuilman et al., 2008). These findings 
support the new idea of which senescent cells dictate senescence microenvironment. 
The SASP secretes soluble factors that include interleukins, chemokines, growth 
factors/regulators, inflammatory factors, proteases, receptors, ligands, PGE2, nitric 
oxide and ROS. These molecules affect the innate immune response for tumor 
clearance, turn other cells into senescent cells for tumor suppression, or reinforce 
senescence through the maintenance of DDR (Acosta et al., 2008b; Coppe et al., 2010; 
Fumagalli and d'Adda di Fagagna, 2009).  
SASP is not activated by “typical” senescent pathways such as p16-pRb and p53-p21. 
As described above, p16 and p21 are cyclin-dependent kinase inhibitors that lead to 
cell cycle arrest, a prerequisite of cellular senescence. However, the activation of 
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SASP is not p16-dependent or simply an inevitable consequence of p16-induced 
senescence (Coppe et al., 2010). In contrast, the activation of p53 inhibits SASP and 
promotes cell autonomous regulation (Coppe et al., 2008). With this in mind, it is 
helpful to extrapolate cellular senescence to organismal aging. The p53 signaling is 
getting insensitive with age, but the inflammatory signaling is getting sensitive. As 
such, SASP-mediated non-autonomous regulation dominates over the p16- or p53-
dependent autonomous pathway. This supports the microenvironment theory of SASP 
through cell non-autonomous regulation (Salminen and Kaarniranta, 2010).  
The p38-NFκB pathway also plays a pivotal role in the regulation of SASP. The p38 
MAPK is a stress-induced kinase that is greatly activated upon induction of 
senescence. Different from DDR that may not always activate SASP, p38 induction is 
sufficient to turn SASP on (Freund et al., 2011). The p38 MAPK pathway activation 
transmits signals to NFκB, which serves as the effecter transcription factor for 
transactivation of secretary factor expression. Interestingly, senescence induction by 
the oncogenic Ras can be reversed by knocking down NFκB (Chien et al., 2011; 
Salminen and Kaarniranta, 2010; Salminen et al., 2011). Thus, senescence 
microenvironment can be modulated by inflammatory response in SASP.  
1.3.2.6 Lamin B1 underexpression 
Lamins are nuclear structural proteins that reinforce nuclear envelope integrity and 
genome stability. Nuclear envelope restricts the genome in the nucleus at the 
proximity of outer membrane, inner membrane, nuclear pore complex and the lamina. 
The A- and B-type lamins comprise lamina. In mammals, A-type lamins, lamin A and 
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lamin C, are encoded by the LMNA gene, whereas the two major types of B-type 
lamins, lamin B1 and lamin B2, are transcribed from LMNB1 and LMNB2 gene, 
respectively. Generally, A-type lamins mainly express in fully differentiated cells 
while B-type lamins express throughout the cell development (Rober et al., 1989; 
Schatten et al., 1985). Interestingly, mutations in A-type lamins lead to several human 
diseases, including Emery-Dreifuss muscular dystrophy, dilated cardiomyopathy, 
atypical Werner syndrome and Hutchinsom-Gilford progeria (Lammerding et al., 
2006). Lamins provide critical structural barriers against genome instability through 
DNA repair, DNA replication, transcription control and chromatin organization 
(Dechat et al., 2008; Kennedy et al., 2000; Kumaran et al., 2002; Manju et al., 2006; 
Moir et al., 1994). However, human genetic diseases are more likely to be developed 
by A-type than by B-type lamin mutations because of the prominent role of lamin A 
in nuclear structural stability.  
Lamin B1 is a newly identified marker of cellular senescence. Lamin B1 is not as 
ubiquitous as lamin B2 in human tissues, and its expression is highly associated with 
cell proliferation. Not only in senescent cells, lamin B1 expression is also maintained 
in proliferative and quiescent cells (Broers et al., 1997). However, the expression of 
lamin B1 is decreased under either p53 or pRb pathway activation. The turnover rate 
of lamin B1 protein and mRNA is great in senescent cells (Freund et al., 2011).  
1.3.3 The many roles of cellular senescence  
Cellular senescence helps tissue regeneration and protects cells against tumorigenesis. 
Cellular senescence arrests damaged cells from proliferation, eventually removing them 
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from the organs or tissues to facilitate replenishing new cells from stem cells or to 
prevent tumorigenesis. Cellular senescence can also counteract tumorigenesis by 
activation of DNA damage response (Bartkova et al., 2005; Gorgoulis et al., 2005). 
Additionally, based on a mouse model of aging, senescent cell removal by inducible 
apoptosis can protect tissues and organs against age-associated disorders in older animals 
(Baker et al., 2011). Similarly, cellular senescence can be activated by trace elements 
such as selenium compounds in the prevention against tumorigenesis. The Cheng Lab has 
previous shown that doses of selenium less than LD50 can induce senescence and DNA 
damage responses in non-cancerous but not cancerous cells, suggesting that 
tumorigenesis can be stifled at the very early stage by selenium-induced activation of 
early tumorigenesis barriers (Wu et al., 2010; Wu et al., 2011).  
Strikingly, senescence can promote both aging and carcinogenesis. Senescent cells 
exhibit senescence-associated secretary phenotype that modulates the microenvironment. 
Such cell non-autonomous regulation may accelerate cellular senescence in surrounding 
cells or the proliferation of pre-malignant cells. Accumulation of senescent cells leads to 
tissue or organ degeneration. In lamin A-defective mice, senescence-associated secretary 
phenotype induces systematic inflammation that is driven by NF-κB transactivation 
through ATM activation. Interestingly, the aging-associated symptoms in the mice are 
reversed by inhibition of NF-κB transactivation. These results reinforce the theory of cell 
non-autonomous regulation by senescent cells that can promote aging in the whole body 
scale (Osorio et al., 2012). In addition, senescence-associated secretary phenotype 
facilitates the proliferation of pre-malignant cells through the secretary cytokines and 
chemokines. Through this microenvironment change, pre-malignant cells prone to 
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transformation into malignant cells. Thus, cellular senescence is a double-edged sword 
not only to prevent carcinogenesis and tissue regeneration, but also to promote aging and 
tumorigenesis.  
Is cellular senescence beneficial or detrimental to multicellular organism? Proteins in the 
senescence-associated pathway are critical in determining how the cell senesce. To 
establish cellular senescence, activated effectors in senescence pathway are required to 
halt cell proliferation. However, the ATM-p53 pathway is critical for the process against 
tumorigenesis by the activation of cellular senescence (de Keizer et al., 2010). 
Compromised genome stability can activate DNA damage response. Although ATM and 
p53 are known to play a central role in the activation of cellular senescence in damaged 
cells, the detail molecular mechanism by which they modulate senescence is largely 
unknown. Understanding the role of ATM and p53 in the interphase between aging and 
longevity or between carcinogenesis and cancer suppression is critical for future 
biomedical research, in an attempt to redefine or redevelop the remedy of cancer and/or 
aging interventions (Campisi, 2011). 
1.4.1 ATM activation in DDR (DNA damage response) 
ATM plays a central role in DDR by transducing the DNA damage signals to 
downstream effectors by its catalytic activity of phosphorylation, resulting in checkpoint 
activation, DNA repair and cell death. Although DNA DSB has been shown to be 
recognized by various markers, the most significant one perhaps is poly(ADP-ribose) 
polymerase 1 (PARP1) that recruits Mre11-Rad50-NBS1 (MRN complex) to the DNA 
DSB site (Ciccia and Elledge, 2010; Haince et al., 2008). In turn, ATM is recruited by 
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MRN complex and subsequently phosphorylates NBS1 and other proteins for S-phase 
checkpoint activation (Lim et al., 2000; Wu et al., 2000; Zhao et al., 2000). By using 
purified proteins, it has been shown that ATM pathway activation is initiated by ATM 
autophosporylation at Ser-1981 in the response to DNA DSB or oxidative stress (Guo et 
al., 2010; Lee and Paull, 2005). Another two kinases in the same family are the catalytic 
subunit of the DNA-dependent protein kinase (DNA-PKcs) and ataxia telangiectasia and 
Rad3 related (ATR). Together with the Ku70/Ku80 sensor proteins, DNA-PKcs repairs 
DNA DSB by NHEJ (Reynolds et al., 2012). Another kinase in this protein family is 
Ataxia telangiectasia and Rad3 related (ATR). These three kinases may have dependent 
and independent roles in DDR. It was reported that ATM and DNA-PKcs collaborate in 
the response to DBS (Chen et al., 2007; Martin et al., 2012; Shrivastav et al., 2008). 
Moreover, MRN complex cooperates with ATM to resect a DSB end for the generation 
of a 3’-single strand tail that recruits replication protein A (RPA), setting a stage for 
ATR-dependent homologous recombination repair of DNA DSB. Similarly, ATRIP is a 
sensor of DNA damage and recruits ATR to the site of DNA damage (Falck et al., 2005). 
If left unrepaired, persistent DDR follows. ATM can also phosphorylate p53 (Banin et al., 
1998; Canman et al., 1998), resulting in increased levels of p53 that promotes cellular 
senescence or programmed cell death. Because ATM has been known to phosphorylate 
hundreds of substrate in the response to DDR (Kastan and Lim, 2000), ATM is critical to 
control various cellular functions in response to different types of DNA damage, 
including DSB and oxidative DNA damage.  
Activated ATM regulates p53 functions directly and indirectly by different modifications 
on various sites. In proliferating cells, the half-life of p53 is short (30 min) because 
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MDM2 is constitutively associated with p53 and shuttles p53 from nucleus to cytosol for 
proteolytic degradation (Khosravi et al., 1999; Maya et al., 2001). However, activated 
ATM phosphorylates MDM2 at Ser-395, resulting in dissociation of p53 from MDM2 
and the subsequent increased p53 steady state level. The dissociation of p53 from MDM2 
is further reinforced by p53 phosphorylation at Ser-20 by CHK2, the residue critical for 
MDM2 binding (Chehab et al., 2000; Hirao et al., 2000). This modification increases 
steric hindrance of the MDM2-p53 interaction. Furthermore, activated ATM can 
phosphorylate p53 at Ser-15 and can also increase p53 stability, resulting in increased 
p53 transactivation activities (Canman et al., 1998; Dumaz and Meek, 1999; Khanna et 
al., 1998). The direct or indirect modifications by ATM determine the activity or stability 
of p53, promoting cellular senescence and/or apoptosis. 
1.4.2 The function of p53  
Although p53 serves as a tumor suppressor and prevents carcinogenesis, this protein is 
usually mutated during tumorigenesis. p53 was first recognized as a tumor cell specific 
antigen in both humans and mice, with its function being designated as cell 
transformation-activating protein or oncogene (Crawford et al., 1981; DeLeo et al., 1979). 
However, the observed transformation-activating feature of the oncogenic Ras or Myc is 
attributed to p53 mutations (Hinds et al., 1989). On the contrary, overexpression of wild-
type p53 compromises the transformation-activating functions in tumorigenesis (Eliyahu 
et al., 1989; Hinds et al., 1989). In animal models, robust expression of the carboxy-
terminal p53 can reduce the incidence of tumor formation (Tyner et al., 2002). On the 
other hand, mice introduced with additional copies of p53, known as “super p53” mice, 
are more resistant to tumor formation (Garcia-Cao et al., 2002). Additionally, most types 
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of human cancer harbor p53 mutations during tumorigenesis, and more than 80% of the 
mutations are missense mutations (Soussi, 2011). Based on these new strategies to 
analyze unbiased mutations of p53, over 80% of the breast cancer tumors harbor 
mutations, and in some cases there are at least three mutation sites(Edlund et al., 2012; 
Szymanska and Hainaut, 2003). p53 mutations can also be used as a biomarker for cancer 
diagnosis (Szymanska and Hainaut, 2003). In conclusion, available lines of current in 
vitro or in vivo evidence point to a critical role of p53 in the protection against 
tumorigenesis. 
p53 regulates cellular functions by transactivating or repressing target genes. This is 
executed by the following four domains: transactivation, DNA binding, tetramerization 
and nuclear localization. Activated p53 forms a tetramer and serves as the transactivator 
targeting p53 response element, which is a consensus sequence composed of two 10-base 
decamers and a 0-13 base spacer in between. Although the functional response element 
usually has only less than 3 nucleotides at spacer, sometimes a noncanonical element 
exists in the active p53 response element (Menendez et al., 2009). With both 
transactivation domain and DNA binding domain at the N-terminus, p53 regulates the 
transcription of genes involved in redox regulation, metabolism regulation, DNA repair, 
autophagy, cell cycle arrest, cellular senescence and apoptosis (Table 1). However, in 
other cases, p53 works differently and suppresses the transcription of downstream genes 
(D'Souza et al., 2001; Li et al., 2004). 
Furthermore, p53 can serve as an effecter protein in the response to DNA damage 
response and protects cells against tumorigenesis by the activation of cellular senescence. 
The majority of senescence inducers can activate DNA damage response. When DNA 
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damage response is activated, p53 stability is increased by ATM phosphorylation on Ser-
15 and other sites. Then, p53 transactivates p21 expression that inhibits CDK2-cyclin E, 
resulting in G1/S arrest (Brugarolas et al., 1995). Additionally, p53 also possibly 
promotes G2/M arrest through 14-3-3 complex (Hermeking et al., 1997). Because the 
activation of cell cycle arrest is a pre-requisite of cellular senescence, p53 is the key 


















Inhibition Species Reference 
Anti-stress       





Glutathione S-transferase P1 (GSTP1) Activation  human 
(Lo et al., 
2008) 
Interferon regulatory factor-2-binding protein-2 




Serine/Threonine kinases 17A Activation  human 
(Mao et 
al., 2011) 
Glutathione peroxidase 1 Activation  human 
(Tan et al., 
1999) 
Metabolism       
Metalloproteinases-3 Activation mouse 
(Bian et 
al., 1996) 




Smooth muscle alpha-actin Activation human 
(Comer et 
al., 1998) 
Human Metalloproteinase-1 Inhibition human 
(Sun et al., 
1999b)  
Thiamine transporter 1  Activation mouse 
(Lo et al., 
2001) 
Staf50 (TRIM22) Activation human 
(Obad et 
al., 2004) 











Vitamin D receptor Activation human 
(Maruyam
a et al., 
2006) 










Brain-expressed RING finger protein Activation human 
(Cheung et 
al., 2010) 


















DNA damage repair        
GADD45 Activation human 
(Zhan et 
al., 1993) 




Ribonucleotide reductase (p53R2) Activation human 
(Nakano et 
al., 2000) 








Pierce 1 Activation Mouse 
(Sung et 
al., 2010) 




















Xeroderma pigmentosum, complementation group Activation Human (Adimoola
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C m and 
Ford, 
2002) 
Cell cycle       
Cyclin G Activation Rat 
(Zauberma
n et al., 
1995) 
p22/PRG1 Activation Rat 
(Schafer et 
al., 1998) 
PTGF-β Activation Human 
(Tan et al., 
2000) 
DDA3 Activation Mouse 
(Lo et al., 
1999) 




Protein regulator of cytokinesis Inhibition Human 
(Li et al., 
2004) 
SMART1 Activation Human 
(Singh et 
al., 2007) 
DEC1 Activation Human 
(Qian et 
al., 2008) 
Prl-3 (phosphatase of regenerating liver-3) Activation Human 
(Basak et 
al., 2008) 




Necdin Activation Mouse 
(Lafontain
e et al., 
2012) 
Murine double minute 2 Activation Mouse 
(Juven et 
al., 1993) 
14-3-3 protein Activation Mouse 
(Hermekin
g et al., 
1997) 
B99 Activation Mouse 
(Utrera et 
al., 1998) 
Insulin growth factor-binding protein 3 Activation Human 
(Buckbind
er et al., 
1995) 




Apoptosis       









mRTVP-1 Activation Mouse 
(Ren et al., 
2002) 
Snk/Plk2 Activation Mouse 
(Burns et 
al., 2003) 
CD200 Activation Mouse 
(Rosenblu
m et al., 
2004) 
SIVA Activation Mouse 
(Fortin et 
al., 2004) 
Decoy receptor 2  Activation Human 
(Liu et al., 
2005) 
Epithelial cell kinase Activation Human 
(Jin et al., 
2006) 








APLP1 Activation Human 
(Tang et 
al., 2007) 
Beta 1, 4 GalTII Activation Human 
(Zhou et 
al., 2008) 




TNFSF10 (TRAIL) Activation Human 
(Kuribaya
shi et al., 
2008) 
S100 calcium-binding protein A9 (S100A9) Activation Human 
(Li et al., 
2009) 









Foxo3 Activation Mouse 
(Renault et 
al., 2011) 

















PAG608 Activation Mouse 
(Israeli et 
al., 1997) 
p53-regulated Apoptosis-Inducing Protein 1 
(p53AIP1) Activation Human 
(Oda et 
al., 2000) 
p53-dependent damage-inducible nuclear protein 




Apoptosis protease-activating factor 1 Activation Human 
(Moroni et 
al., 2001) 
PERP Activation Mouse 
(Attardi et 
al., 2000) 
PIDD Activation Human 
(Lin et al., 
2000) 
 
Table 1 p53-regulated genes in anti-stress, metabolism, DNA repair, cell cycle and 









1.4.3 Linking DNA damage to senescence 
The biological function of cellular senescence remains an open field to be explored. 
Cellular senescence in vivo and in cultured cells is induced by various inducers and is 
characterized by various markers. Increasing lines of evidence indicate that cellular 
senescence can be induced by DNA damage, chromatin alteration, and DNA damage 
independent pathways (Nakamura et al., 2008; Pospelova et al., 2009; Prieur et al., 2011). 
The phenotypes of senescent cells are variable and are thought to modulate various 
physiological functions. The decrease in lamin B is independent of p38MAPK-NFκB 
pathway, ROS, or DDR, but activates p53 and p16 pathways toward senescence 
induction. On the contrary, cellular senescence induced by chromatin perturbation is p53 
and p16 independent. Also, there may have cell type-specific senescence phenotypes in 
the response to various stimuli (Coppe et al., 2011; Freund et al., 2012; Kosar et al., 
2011).  
p53 participates in the major pathway against tumorigenesis, but the crosstalk between 
p53 and other pathways represent another autonomous or non-autonomous regulation of 
cell fate.  As described above, “super p53” mice with additional copies or constitutive 
expression of p53 are resistant to tumorigenesis (Garcia-Cao et al., 2002; Tyner et al., 
2002). As aging progressed, DDR and dysfunction telomere activate p53, resulting in 
restriction of pre-malignant cells in senescence instead of tumorigenesis. However, in 
some cases, p53/p21 and p16 are thought to initiate and maintain cellular senescence, 
respectively (Beausejour et al., 2003; Robles and Adami, 1998). Crosstalk between p53 
and pRB pathways may involve the intermediate p16, which regulates p21 accumulation 
by transcriptional or post-translational regulation to reinforce cellular senescence (Al-
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Mohanna et al., 2007; Mitra et al., 1999). Interestingly, in immortal cells, the 
overexpression of exogenous p21 promote demethylation at the promoter of p16. Thus, 
the expression of p16 is restored for induction of growth arrest or cellular senescence 
(Wu et al., 2012). The p16-pRb pathway is not a redundant pathway to activate cellular 
senescence for anti-tumorigenesis; rather, it is an important pathway meant to secure the 
cooperation with p53 and p21 and to keep normal cellular functions. Ultimately, if the 
regulation of cellular senescence is properly controlled by effectors, the individual will 
likely to age slowly with decreased incidence of cancer. 
1.5 Selenium 
Selenium is an essential trace element for optimal health. Current Dietary Reference 
Intake (DRI) information on the Recommended Dietary Allowance (RDA) of selenium 
for USA is below 40 µg/day for children under 13 years of age children, but RDA of 
selenium for those age above 14 is 55 µg/day. The special requirements during pregnancy 
and lactation are 60 µg/day and 70 µg/day, respectively 
(http://iom.edu/Activities/Nutrition/SummaryDRIs/~/media/Files/Activity%20Files/Nutri
tion/DRIs/RDA%20and%20AIs_Vitamin%20and%20Elements.pdf, USDA). Although 
certain foods are rich in selenium, such as Brazil nuts, seafood and dairy products, body 
selenium status is largely correlated to the level of selenium in the soil. In the United 
States, the intake of selenium tends to fall between 50~200 µg/day, which is considered 
as safe and adequacy. The extreme cases were reported elsewhere such as China, where 
the intake had been reported to fall between 7~3800 µg/day, resulting in selenium 
deficiency or toxicity (Ehrlich, 2002). However, to maintain the optimal health, there is a 
U-shaped relationship between selenium intake and the risk of diseases. Selenium 
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deficiency may cause Keshan disease or Kashin-Beck disease (Fairweather-Tait et al., 
2011), which are caused by Coxsackie B virus and fungus produced mycotoxin, 
respectively. The proposed etiology of these two diseases is the defective antioxidant 
functions, as selenium deficiency decreases selenoprotein expression, the majority of 
which are antioxidant. On the other hand, when selenium intake reaches a toxic level, the 
excessive amount of selenium may induce the formation of ROS and the resultant 
selenosis (Yang et al., 1983). The Nutritional Prevention of Cancer (NPC) clinical trial 
conducted in the United States has indicated that the daily oral administration of selenium 
at 200 µg, which is 3-4 folds higher than nutritional needs, significantly decreases risks 
of prostate, lung, and colon cancers (Clark et al., 1996). The effect of chemoprevention 
might be resulted from excessive amount of selenium, because selenium in excess is pro-
oxidant instead of antioxidant. The generation of ROS by excessive selenium may restrict 
pre-malignant cells from turning into malignant cells (Wu et al., 2010). Although results 
of the follow-up clinical trial, the Selenium and Vitamin E Cancer Prevention Trial 
(SELECT), do not support a beneficial role of selenium in chemoprevention, the 
discrepancies are largely addressed on the National Cancer Institute's website, from 
which it seems like that the inconsistent results may be attributed to the form of selenium 
(selenized-yeast vs. selenomethionine) or the basal level of selenium in volunteers (NPC, 
low vs. SELECT, high) (http://www.cancer.gov/newscenter/qa/2008/selectqa#que5, NCI). 
Clearly, additional clinical studies are needed to elucidate or re-confirm a role of 
selenium in cancer prevention. Therefore, in terms of obtaining optimal health, keeping 
selenium intake within adequate level is necessary for optimal health through the 




1.6.1 Selenoprotein Biosynthesis 
Selenium is incorporated into selenoproteins through selenocysteine. In general, there are 
20 amino acids in humans for protein translation. Nevertheless, selenocysteine has been 
identified to be the 21st amino acid in prokaryotic and eukaryotic cells. The reactions of 
selenocysteinyl-tRNA biosynthesis in eukaryotes are not understood completely. It is 
proposed that seryl-tRNA is formed, followed by selenocysteine synthase formation to 
incorporate selenium in serine and generate selenocysteryl-RNA (Stadtman, 1996).   
Selenocysteine incorporation into selenoproteins needs SECIS element. Since all codons 
are assigned to specific amino acids, selenocysteine uses another strategy to insert this 
amino acid into selenoproteins. First, the codon for selenocysteine is shared with one for 
translation termination, UGA. To distinguish these two events, there is a special sequence 
for selenocysteine tRNA recognition, known as SECIS element (Berry et al., 1993; Burk 
and Hill, 1993; Papp et al., 2007). The SECIS element forms a stem and loop structure, 
which can be recognized by SECIS-binding protein 2 (SBP2) that bends mRNA 
structures to facilitate selenocysteine tRNA recognition and (Low et al., 2000). This 
unique SECIS elements intrinsic in all selenoprotein genes is used as the strategy to 
search against the whole human and mouse genome for identification of all possible 
selenoproteins, resulting in the conclusion that there is a total of 25 selenoproteins in 
humans (Kryukov et al., 2003; Kryukov et al., 1999). 
1.6.2 Selenoproteins in human genome 
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The expression of selenoproteins responds to body selenium status. There are three 
potential ways to alter the expression of selenoproteins, including transcription, post-
transcriptional modification, and the sources of selenium (Burk and Hill, 1993). The post-
transcriptional modification is critical for the maturation of selenocysteine-tRNA, and the 
sources of selenium determine the available material for selenocysteine biosynthesis. 
Futhermore, regulation of selenoprotein mRNA expression by dietary selenium status has 
been well studied (Kipp et al., 2009; Sunde, 2010; Sunde and Raines, 2011). 
Selenoproteins play numerous functions in the cell, especially redox-related functions. 
Based on current understanding, selenoproteins play critical roles in redox regulation and 
signaling, thyroid hormone metabolism, selenocysteine synthesis, transportation and 
storage of selenium, and protein folding. In humans, the majority of the 25 selenoproteins 
exhibit antioxidative activities (Papp et al., 2007). Interestingly, the localizations of 
redox-related selenoproteins are various in the cell, suggesting that the major function of 
selenoproteins is to deal with oxidative stress in different compartments of the cells 
(Davis et al., 2012). Because of the localization divergence, the importance of 
selenoproteins may act on multiple pathways of redox regulation. 
1.6.2.1 The selenium-dependent glutathione peroxidase family 
The selenium-dependent glutathione peroxidases (GPxs) are critical antioxidant enzymes 
in different compartments of the cell and various tissues to protect against damages from 
oxidative stress. GPxs use glutathione to reduce hydrogen peroxide and organic 
hydroperoxides (Cohen and Hochstein, 1963). GPx (now GPx1) was first found as an 
enzyme to protect hemoglobin from oxidative breakdown in erythrocytes (Mills, 1957). 
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In February 1973, Rotruck et al. reported for the first time that GPx1 is a selenium-
containing protein (Rotruck et al., 1973). This seminal contribution was confirmed by a 
paper published 3 months later from the Flohe group (Flohe et al., 1973). Since 2003, the 
consensus is that there is a total of five selenium-containing glutathione peroxidases in 
humans whose expression is tissue-specific. GPx1 expresses in the body ubiquitously, but 
is especially high in blood, kidney, liver and placenta. GPx2 is abundant in 
gastrointestinal tract, liver and mammary gland. The extracellular GPx3 is highly 
expressed in and secreted from epididymis, kidney and plasma, and resides in plasma. 
Phospholipid hydroperoxide GPx (GPx4) abundantly expresses in liver and testis. GPx6 
is rich in embryo and olfactory epithelium (Kryukov et al., 2003). In terms of cellular 
distribution, current understanding indicates that 1) GPx1 localizes to cytoplasm and 
mitochondria, 2) GPx2 distributes in cytoplasm and possibly in Golgi apparatus, 3) GPx3 
is in extra cellular space, and 4) GPx4 exists in cytoplasm, mitochondria and nucleus 
(Brigelius-Flohe and Maiorino, 2013; Brigelius-Flohe et al., 2001). Little is known about 
the cellular localization of GPx6.  
GPx1 plays a pivotal role in the mitigation of oxidative damage (Cheng et al., 1998), 
which accounts for the majority of the peroxide-decomposing activity of selenium. A role 
of the GPx proteins in tumorigenesis has been extensively studied. GPx1 in principle can 
prevent the formation of oxidative DNA damage and suppress tumorigenesis (Brigelius-
Flohe and Kipp, 2009; Esposito et al., 1999; Sandstrom and Marklund, 1990). Consistent 
with this notion, GPx1 can be transactivated by the tumor suppressor p53, resulting in 
declined oxidative stress (Tan et al., 1999). Similarly, overexpression of GPx1 
counteracts tumorigenesis by the induction of Gadd45 expression for reinforcement of 
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cell cycle arrest (Nasr et al., 2004). GPx1 is also implicated in the protection against 
cardiovascular disease, neurodegeneration and autoimmune disease (Lei et al., 2007). 
However, the role of GPx1 in health promotion is controversial. Although increased 
oxidative stress is associated with many metabolic and age-related degenerations, 
increasing GPx1 expression above the physiological level may not necessarily beneficial. 
Intriguingly, GPx1 overexpression mice developed insulin resistance and glucose 
intolerance (McClung et al., 2004). On the contrary, GPx1 knockout mice on a high-fat 
diet are more resistant than wild type animals to develop insulin resistance and glucose 
intolerance (Loh et al., 2009). Likely, GPx1 can regulate hydrogen peroxide status in 
insulin signaling pathways (Veal et al., 2007). GPx2 may promote early stage 
carcinogenesis, but later inhibit cancer cell growth, invasion and migration (Brigelius-
Flohe et al., 2001). Overexpression of GPx3 in mice may inhibit cancer cell growth and 
metastasis (Brigelius-Flohe and Kipp, 2009). Lastly, GPx4 overexpression in mice is 
known to inhibit the growth of tumor and stop metastasis (Brigelius-Flohe and Kipp, 
2009).  
1.6.2.2 Thioredoxin (Trx) signaling 
In mammals, there are three thioredoxin reductases (TrxRs) that play various cellular and 
physiological functions. They are the cytosolic and extracellular TrxR1 (Tamura and 
Stadtman, 1996), the mitochondrial TrxR2 (Miranda-Vizuete et al., 1999), and the 
thioredoxin glutathione reductase, TrxR3 (Sun et al., 1999a). TrxRs are the members of 
the pyridine nucleotide-disulfide oxidoreductase family in mammalian cells and play 
critical roles in the recycling of oxidized Trx. The Trx system regulates the activity of 
NF-κB, AP-1, p53 and the glucocorticoid receptor, all of which are transcription factors 
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that contain cysteine residue(s) in their DNA-binding domains (Lu and Holmgren, 2009). 
TrxR1 is required for embryonic development. Knockout of TrxR1 in mice leads to the 
accumulation of nonfunctional oxidized rebonuleotide reductase, resulting in impaired 
DNA synthesis (Jakupoglu et al., 2005). Interestingly, TrxR1 was found to be 
overexpressed in malignant cells (Kakolyris et al., 2001; Matsutani et al., 2001; Raffel et 
al., 2003). Different from TrxR1, TrxR2 mainly resides in mitochondria and has been 
linked to the control of apoptotic signaling pathway (Nalvarte et al., 2004). Cells with 
TrxR2 mutations progress in an enhanced rate from G1 to S phases of the cell cycle, 
consistent with the proposed role of TrxR2 in cell proliferation regulation (Kim et al., 
2003). Because the activities of TrxR are highly related to carcinogenesis, they are 
promising targets for cancer therapeutics (Klossowski et al., 2011).  
 
1.6.2.3 Thyroid hormone metabolism 
Iodothyronine deiodinases (DIO) regulate thyroid hormone maturation and maintain 
optimal health span. There are three DIOs in this family of proteins, which regulate the 
conversions between different forms of thyroid hormones, thyroxine (T4), 3,5,3’-
triodothyronine (T3) and reverse triiodothyronine (rT3). DIO1 is mainly located in the 
liver, kidney, and thyroid. DIO2 expresses highly in brain, pituitary, thyroid, skeletal 
muscle and brown adipose tissue. DIO3 is abundant in placenta and uterus during 
pregnancy, as well as in cerebral cortex and skin (Davis et al., 2012). T4, the major 
hormone secreted from thyroid gland, requires DIO1 and DIO2 to catalyze the 
deiodination of T4, resulting in the formation of the active thyroid hormone, T3. In DIO1 
or DIO2 knockout mice, the level of T3 in serum is normal (Galton et al., 2009), but 
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DIO2 knockout mice retain higher level of T4 in serum and show impairment in hearing, 
thermogenesis and neurocognition (St Germain et al., 2009). The phenotypes of DIO3 
knockout mice include increased prenatal mortality, growth retardation, impaired fertility, 
hyperthyroidism in prenatal period and hypothyroidism in adulthood (St Germain et al., 
2009). Since thyroid hormones are involved in the signaling regulation of differentiation, 
proliferation and apoptosis, DIOs may also mediate carcinogenesis. Increased expression 
of DIO3 has been shown to promote tumor proliferation (Piekielko-Witkowska and 
Nauman, 2011). Furthermore, DIO1 protein expression is decreased in various cancer 
types, including papillary thyroid cancer, papillary thyroid carcinoma, renal cell 
carcinoma, lung cancer, prostate cancer and hepatic adenoma. However, DIO2 protein 
expression is increased in follicular thyroid carcinoma, anaplastic thyroid cancer, 
medullary thyroid cancer, astrocytoma, gliosarcoma, glioblastoma and pituitary tumor. 
Furthermore, DIO3 protein expression is increased in liver hemangioma, gliomas, 
gliosarcoma, glioblastoma and pituitary tumors (Casula and Bianco, 2012). Because 
DIO1-3 change their protein expression in cancer cells, they are candidate biomarkers for 
cancer diagnosis and therapy. 
1.6.2.4 Selenium transportation and storage 
Selenoprotein P (Sepp1) transports and stores selenium to retain optimal health. Sepp1 is 
a plasma selenoprotein with 4 isoforms, the full-length of which contains 10 residues of 
selenocysteine (Burk and Hill, 2009; Himeno et al., 1996). Sepp1 is mainly synthesized 
in liver, heart, lung and kidney and secreted to extracellular fluids including plasma 
(Burk and Hill, 1994). Sepp1 is critical for selenium retention and transportation in the 
body. Sepp1 knockout rats show an increased level of selenium excreted through the 
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urine system (Burk et al., 2006). Sepp1 is responsible for selenium delivery in testis and 
brain (Hill et al., 2003; Schomburg et al., 2003) through the receptor-mediated uptake by 
apolipoprotein E receptor-2 (apoER2), whereas Sepp1 is uptaken by megalin in kidney 
(Olson et al., 2008; Olson et al., 2007). In addition to the well accepted role as a Se 
transporter, Sepp1 is also implicated in the development of spermatogenesis and the 
prevention of brain degeneration (Burk and Hill, 2009).  
1.6.2.5 Other notable selenoproteins 
Proteins in the Sep15 family, Sep15 and selenoprotein M, control the quality of protein 
folding in endoplasmic reticulum (ER) (Ferguson et al., 2006). Sep15 expresses highly in 
liver, kidney, testes and prostate (Davis et al., 2012), whereas selenoprotein M is mainly 
found in brain. Sep15 cooperates with the chaperon enzyme UDP-glucose:glycoprotein 
glucosyltransferase (UGGT) to regulate protein folding in ER (Korotkov et al., 2001). 
Sep15 may also participate in the disulfide bond modification of unfolded and misfolded 
proteins (Labunskyy et al., 2007). Furthermore, a recent report implicates Sep15 in the 
promotion of tumorigenesis and metastasis of colon cancer (Irons et al., 2010). 
Selenoprotein H (SelH) is potentially a dual function protein involved in redox regulation 
and transactivation of phase II antioxidants; however, the mechanism of actions are 
mainly unknown. In mice, SelH mRNA is mainly expressed in brain, thymus, lung, testes 
and uterus (Novoselov et al., 2007). In humans, some cancer cell lines, including the 
colorectal HCT116 and prostate LNCaP cells, show increased expression of SelH mRNA. 
SelH was initially identified as a thioredoxin reductase homologue with glutathione 
peroxidase-like activity (Novoselov et al., 2007). Overexpression of human SelH in 
mouse HT22 neuronal cells improves cell survival after UVB irradiation through the 
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suppression of superoxide production (Ben Jilani et al., 2007). Moreover, SelH-
overexpressed cells show elevated mitochondrial biogenesis and functions (Mendelev et 
al., 2010). In addition to being an antioxidant, SelH has been demonstrated as a potential 
transcription factor (Panee et al., 2007). Based on the protein domain searching, SelH 
carries an AT-hook domain, such that it can potentially bind DNA minor grooves for 
transactivation of the targeted genes. Panee et al used chromatin immunoprecipitation 
assays to demonstrate that GFP-tagged SelH protein appeares on heat shock element 
(HSE) and stress response element (STRE) (Panee et al., 2007). Additionally, results 
from a recent publication have shown that metal transcription factor-1  binds to metal 
response element (MRE) on SelH promoter for transactivation (Stoytcheva et al., 2009). 
Because oxidative stress can possibly be induced by heavy metals, SelH expression in 
principle is upregulated upon oxidative stress. Lastly, SelH is known to be localized to 
nucleoli under the condition of GFP-tagged SelH overexpression in NIH 3T3 cells 
(Novoselov et al., 2007), suggesting a role for SelH in rDNA metabolism.  
Available lines of recent evidence suggest critical physiological roles of other less-
characterized selenoproteins in optimal health. Selenoprotein N (SelN) mutations lead to 
a human genetic disorder, rigid spine muscular dystrophy. SelN potentially suppresses 
muscle disorder through the protection against protein oxidation, calcium handling 
abnormalities and predisposition to oxidative stress (Arbogast and Ferreiro, 2010; Castets 
et al., 2012). Selenoprotein W (SelW) is highly expressed in muscle, heart, spleen and 
brain, and plays important roles in human immune responses and thioredoxin-dependent 
redox pathway (Whanger, 2009).  Selenoprotein R (SelR), also known as methionine 
sulfoxide reductase B (MsrB), is one of the enzymes in the Msr system, and the 
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expression of SelR is closely associated with the level of dietary selenium. Maintaining 
functional Msr system in the cell prevents protein-carbonyl adducts and protects cells 
against aging and age-related neurodegereration (Moskovitz and Oien, 2010; Oien and 
Moskovitz, 2009). Future studies on mechanistic and physiological investigation of these 
and other newly identified selenoproteins will provide critical insight into the battle 
















Chapter 2: Materials and Methods 
2.1 Cell culture and reagents 
The MRC-5 human diploid lung fibroblasts (Coriell Institute, Camden, NJ) were cultured 
at 37   in 20% O2 or in 3% O2 in minimum Eagle’s medium (Mediatech Inc., Herndon, 
VA) supplemented with 15% heat-inactivated fetal bovine serum, 1 ng/ml essential 
amino acid, 1 ng/ml nonessential amino acid, 1 ng/ml vitamins, and 100 units/ml 
penicillin and streptomycin. HeLa cervical cancer cells (ATCC, Manassas, VA) and 
HCT116 human colorectal adenocarcinoma cells complemented with hMLH1-expressing 
vector (HCT116+hMLH1) (Koi et al., 1994; Yanamadala and Ljungman, 2003) were 
maintained at 37   in 20% O2 in Dulbecco’s modified Eagle’s medium (Mediatech Inc., 
Herndon, VA) supplemented with 10% heat-inactivated fetal bovine serum and 100 
units/ml penicillin and streptomycin. N-acetylcysteine (NAC) (Sigma-Aldrich), a 
glutathione mimic agent, was dissolved in water. KU 60019 and KU 55933 (Tocris, 
Ellisville, MO) were dissolved in Dimethyl sulfoxide (DMSO).  
2.2 Stably knockdown by shRNA  
The lentivirus-based strategy was used to deliver specific short hairpin RNA (shRNA)-
containing cassette for the generation of stable knockdown cells. The human non-target 
scrambled sequence was adapted from Addgene Organization, and SelH and SelH2 
shRNA sequences that target SelH mRNA 333-353 and 503-523, respectively, were 
designed based on the Invitrogen Block-itTM RNAi designer. SelH and scrambled 
targeting sequences are listed in Figure 3.1A. For SelH and scrambled shRNA 
knockdown, the viral particles that contain SelH or scrambled shRNA cassette were 
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produced by BLOCK-iT™ Lentiviral RNAi Expression System (Life technologies). The 
viral particles were used to infect MRC-5, HeLa and HCT116+hMLH1 cells, followed by 
clonal selection. After 24-hour infection, one day recovery and 14-day blasticidin 
selection, a total of 36 clones (3 knockdown sequences) were picked and sub-cultured to 
confirm knockdown efficiency by using real-time PCR. A viable colony is defined as the 
colony with more than 50 cells. p53 shRNA knockdown was performed as described 
previously (Wu et al., 2011).  
2.3 Reactive oxygen species (ROS) detection 
The level of intracellular ROS is detected by using 2', 7'-dichlorodihydrofluorescein 
diacetate (H2DCFDA, Invitrogen). H2DCFDA stock (1 M/ml) was prepared and 
dissolved in DMSO. MRC-5 cells on cover slips were washed with 1 X PBS twice and 
incubated in phenol red free RPMI medium containing 5 µM/ml H2DCFDA for 15 
minutes. Then, the H2DCFDA loaded cells were washed twice with 1 X PBS and 
incubated for additional 15 minutes in dark at 37°C. The fluorescence signal in the 
unfixed cells was detected immediately by the GFP channel under Zeiss AxioObserver 
100 fluorescence microscope (Carl Zeiss) for image acquisition.       
2.4 Senescence Assay 
To evaluate cellular senescence, the activity of senescence-associated β-galactosidase 
(SA-β-Gal) was measured by using a Senescence Detection Kit (BioVision, San 
Francisco, CA). SA-β-Gal is a useful marker to distinguish proliferating and senescent 
cells both in vitro and in vivo (Dimri et al., 1995). MRC-5 cells were seeded onto 12-well 
plates with a density of 10,000 cells/well, and incubated with or without H2O2 (20 µM) in 
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either 3% or 20% O2 incubators. Then, the cells were washed once by 1X PBS, fixed at 
room temperature for 15 min, washed again three times by 1X PBS, and stained with X-
gal at a concentration of 1 mg/ml for 8 h. The staining process was terminated by 
washing the cells in 1X PBS and overlaying in 70% glycerol. The images were captured 
under a light microscope for quantification. 
2.5 Clonogenic Assay 
HeLa and HCT116+hMLH1 SelH and scrambled shRNA cells were seeded in 6-cm dish 
in a density of 750 cells per dish. After 24 hours, attached cells were treated with a 
gradient dose of DNA clastogens, including hydroxyurea (Sigma-Aldrich), 
neocarzinostatin (Sigma-Aldrich), camptothecin (Sigma-Aldrich), paraquat (Sigma-
Aldrich) and hydrogen peroxide (Fisher Scientific) for 24 hours. Then, the drug-
containing media were replaced by a complete medium and cultured for additional 7 days. 
Cells were washed in 1 X PBS, fixed in 90% methanol and stained by 0.5 % crystal violet 
(Alfa Aesar, MA) in 25% methanol. A colony having more than 50 cells is defined as a 
viable one.      
2.6 Immunofluorescence and immunoblotting  
Immunofluorescence and immunoblotting analyses were performed as described 
previously (Qi et al., 2010; Wu et al., 2010). Focus positive cells were defined as those 
containing at least five foci within the nucleus (Maude and Enders, 2005; Qi et al., 2010; 
Wu et al., 2010). Briefly, permeabilized cells were incubated overnight at 4 °C with 
antibodies against H2AX (1:500; Abcam, Cambridge, MA), γH2AX (phospho-H2AX on 
Ser-139, 1:200; Abcam), ATM (1:500; Epitomics, Burlingame, CA), and phospho-ATM 
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on Ser-1981 (pATM Ser-1981, 1:500; Rockland, Gilbertsville, PA). γH2AX and pATM 
Ser-1981 are well-defined markers for DNA breaks and ATM pathway activation, 
respectively (Bakkenist and Kastan, 2003; Lobrich et al., 2010). Six pictures were 
randomly taken from each slide for statistical analysis. For immunoblotting, nuclear 
fraction was isolated by nuclear and cytoplasmic extraction kit (G-Bioscisnce, MO). The 
nuclear extracts were separated by SDS-PAGE and transferred onto a PVDF membrane. 
The blot was incubated sequentially with anti-phospho-Nrf-2 polyclonal antibodies 
(pNrf-2, 1:1000; Epitomics), anti-Nrf-2 polyclonal antibodies (Nrf-2, 1:1000; Santa Cruz 
Biotechnology, Dallas, TX), or anti-Lamin B polyclonal antibodies (Lamin B (C-20), 
1:1000; Santa Cruz Biotechnology, Dallas, TX). After washing, the blots were incubated 
with HRP conjugated secondary antibodies, followed by chemiluminescent reagents 
(Super Signal, Pierce) for signal acquisition. All experiments were performed in duplicate 
and a minimum of three times. 
2.7 Laser micro-irradiation and live cell imaging 
A mixture of oxidative DNA damage and DNA breaks were generated in live cell nuclei 
by laser-induced micro-irradiation using a pulsed nitrogen laser as previously described 
(Chen et al., 2007). The laser system was coupled to a Zeiss Axiovert microscope for live 
cell, time lapse image capture. SelH-GFP (Novoselov et al., 2007) and proliferating cell 
nuclear antigen (PCNA)-DsRed vectors were transiently transfected into MRC-5 cells.    
2.8 Total intracellular glutathione (GSH) detection and apoptotic cells  
Total intracellular GSH is measured by monochlorobimane (mBCl), which forms 
fluorescence adducts with GSH (Franco and Cidlowski, 2006; Sebastia et al., 2003). 
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Adherent cells were collected and preloaded with mBCl (40 µM) in PBS for 10 minutes. 
Then, propyl iodide was added for differentiating live and dead cells. Only dead cells are 
permeable and contain positive propyl iodide signal. The stained cells were immediately 
applied to FACSCanto II flow cytometric analyses (BD Bioscience, CA) to determine the 
level of GSH. The signal was excited with a violet 405 nm laser, and emission was 
acquired with a 450/50 filter. 
Apoptotic cells were determined by mitocapture kit (Biovision, San Francisco, CA) 
staining. Mitocapture in live cells accumulated in mitochondria and showed red 
fluorescence. In apoptotic cells, there is no aggregation of mitocapture so green 
fluorescence was shown. The cells on cover slip were incubated with diluted mitocapture 
(1 µl mitocapture in 1 ml pre-warmed incubation buffer) at incubator for 15 min, and 
washed three times with the incubation buffer. The stained cells were subjected to 
fluorescence microscopy, and observed by GFP and DsRed channels. Eight pictures were 
randomly taken from each slide for statistical analysis.   
2.9 Generation of short telomere mouse  
The Terc+/- mice were provided by Dr. Mark Mattson at the National Institute on Aging 
(Baltimore, Maryland). The Terc+/- mice had been established by backcrossing to >99% 
pure C57BL/6 background before the progressively interbred of Terc-/- mice for the 
generation of late generation short telomere mice used in this study (Blasco et al., 1997). 
The genotypes of G1 progenies were identified by tail-biopsy genomic PCR to select G1 
Terc-/- and Terc+/+ control mice. Then, following the mating scheme (Figure 2.1), the G3 
Terc-/- mice with shorter telomere mice were housed under aseptic conditions in 
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individually ventilated cages within a controlled-temperature (22°C) animal room 
utilizing a 12-h dark:night cycle. Mice had ad libitum access to food and water. These 
experiments were approved by the IACUC Committee at the University of Maryland, 
College Park, an AAALAC accredited campus, and were conducted in accordance with 














Figure 2.1 Breeding scheme Terc+/-, Terc knockout heterozygous; Terc-/-, Terc knockout 










The Torula yeast-based purified diets (Figure 2.2) were formulated based on the AIN-
93G diet (Reeves et al., 1993) and made by Dyets Inc. (Bethlehem, PA, USA). The basal 
(Se-) diet contains 30% Torula yeast and <0.03 mg/kg Se by analysis (AOAC Method 
986.15; Covance Laboratory, Madison, WI, USA). The basal diet was supplemented with 
0.15 mg Se/kg (Se+) as sodium selenate (Holmstrom et al., 2012). Weanling mice were 
fed with the Se- or Se+ diet until they were sacrificed at 12-24 months of age or die 
naturally. The diets for adult mice are based on AIN-93G instead of AIN-93M because 
the former has a higher fat and protein content that better reflects the dietary components 
of Western foods. The diets were stored at -20 °C until feeding and kept for less than 6 














 g/1 kg 




L-Cysteine  3.52 
Cellulose, microcrystalline 50.00 




Choline Bitartrate 2.50 
Vitamin mix2 10.00 
Mineral mix3 35.00 
 
1Basal diet contains <0.03 mg Se/kg diet. 
2Vitamin mix components (per kg diet): niacin, 30 mg; calcium pantothenate, 16.0 mg; 
pyridoxine HCl, 7.0 mg; thiamine HCl, 6.0 mg; riboflavin, 6.0 mg; folic acid, 2.0 mg; 
biotin, 0.20 mg; vitamin E acetate (500 IU/g), 150 mg; vitamin B12 (0.1%), 25.0 mg; 
vitamin A palmitate (500000 IU/g), 8.0 mg; vitamin D3 (400000 IU/g), 2.50 mg. 
3Mineral mix components (per kg diet): CaCO3, 19.43 g; NaCl, 2590 mg; Na2O3Si, 50.75 
mg; KCrS2O8 9.625 mg; CuCO3, 5.005 mg; H3BO3, 2.870 mg; NaF, 2.240 mg; NiCO3, 
1.120 mg; LiCl, 0.595 mg; KIO3, 0.35 mg; (NH4)6Mo7O24, 0.280 mg; NH4VO3, 0.245 mg. 










2.11 Hair graying 
The degree of hair graying was defined as described before (Rudolph et al., 1999). Based 
on the estimated percentage of gray hair on the body, degree of hair graying was scored 
as 0 (0~10%), 1 (10~20%), 2 (20~30%), 3 (30~40%), 4 (40~50%) or 5 (>50%).  
2.12 Additional serum markers    
The fasting and fed plasmas were collected from selenium-deficient and selenium-
adequate mice at age of 12 months and 18 months. The biomarkers (triglyceride, 
cholesterol, glucose, amylase, aspartate aminotransferase, alanine aminotransferase, 
creatine phosphokinase, lactate dehydrogenase, alkline phosphatase, bilirubin, albumin, 
and creatine) were measured by AniLytics Inc. (Gaithersburg, MD). 
2.13 Wound healing experiment 
To perform wound healing experiment (n=5 per group), a skin surgery was operated and 
the recovery was monitored by measuring the size of the wound. Anaesthetic inhalation 
was done by isoflurane before surgery. Then, Nair (Church & Dwight, NJ) was applied to 
the area of skin surgery for hair removal. Then, the bald skin was cleaned by 70% alcohol 
and betadine. The fixed size wound was generated by a 5-mm biopsy punch to perform 
the round shape wound. The biopsy punch cut through the epidermis and dermis, 
reaching panniculus carnosus. In the following 7 days of recovery, the mice were housed 
individually and supplied with sulfamethoxazole/trimethoprim at 1 ml/150 ml in drinking 
water wrapped with aluminum foil. The size of the wound was measured everyday utill 
Day 7.  
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2.14 Bone density determination by micro microtomography (µCT) scanning 
The left femurs were collected from the mice in different dietary and age groups. 
Adherent tissues were removed from femur. Then, the bone was placed in a holder with a 
10.2 mm diameter and scanned by Scanco µCT. The structures of trabecular and cortical 
bone structural indices were determined to acquire bone volume, connectivity density, 
cortical thickness, trabecular number, separation and thickness. We collaborate with Dr. 
Jay Cao (Grand Forks, ND), who has direct experience on this analysis (Cao et al., 2012).  
2.15 Circulating miRNA isolation, microarray and real-time PCR confirmation 
To maximize confidence, a high-throughput platform, TaqMan low density array, was 
used, and the expression of miRNAs was validated by using individual quantitative 
polymerase chain reaction (qPCR) assays (Witwer et al., 2012). To this end, we have 
profiled over 800 miRNAs. To obtain circulating miRNA, 300 µL whole blood was 
collected by 3.2 % sodium citrate (1:9), and plasma was isolated by 2000 x g 
centrifugation for 15 minutes. The total miRNA was isolated by miRNeasy 
Serum/Plasma Kit (Qiagen, Germany). The purified total miRNA was transcribed into 
cDNA by Megaplex RT Primers (Rodent Pool Set) and TaqMan MicroRNA Reverse 
Transcription Kit (Life technologies, CA). Then, cDNAs from pool A and pool B were 
pre-amplified by TaqMan PreAmp Master Mix with Megaplex™ PreAmp Pools. Lastly, 
pre-amplified samples were subjected to microarray analysis by TaqMan OpenArray 
MicroRNA Panels (Life technologies, CA).  
To confirm the differential expression of miRNAs, real-time PCR was used to determine 
the expression of those miRNAs that display significant changes in the microarray 
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analysis. The prepared cDNA from Megaplex RT Primers were pre-amplified by specific 
miRNA primers with TaqMan PreAmp Master Mix. Real-time PCR was performed by 
specific miRNA probe labeled with fluorescence and TaqMan OpenArray Real-Time 
PCR Master Mix (Life technology, CA).   
2.16 Glucose tolerance test and insulin tolerance test 
The mice subjected to glucose tolerance test were fasted overnight (n=6 per group). The 
glucose (1g/kg body weight) was injected into mice by intraperitoneal (ip) injection 
(McClung et al., 2004). For insulin tolerance test, insulin (0.25 U/kg body weight) was ip 
injected and blood drawn every 30 minutes. Blood glucose was measured by CONTOUR 
Blood Glucose Meter (Bayer, Germany). 
2.17 Plasma Insulin and Plasma IGF-1 detection 
Plasma insulin was determined during the time course of glucose tolerance test. Plasma 
insulin was measured by a Mouse Insulin ELISA Kit (ALPCO Diagnostics, NH). For 
each sample, 10 µL plasma was applied into a 96-well plate strip with HRP labeled 
monoclonal insulin antibody cross-linked. After insulin hybridization with the antibody, 
TMB (3,3′,5,5′-tetramethylbenzidine) was added to detect HRP, and the reaction was 
stopped to form yellow color. Then, the microplate reader was used to detect the density 
of the color by the absorbance at 450 nm.  
The plasma IGF-1 was determined at fasting and fed state. Plasma IGF-1 was measured 
by IGF-1 (Mouse/Rat) ELISA Kit (ALPCO Diagnostics, NH). The plate was coated with 
anti-mouse/rat IGF-I antibody, and 50 µL plasma was applied to the plate. After IGF-1 
hybridization with the antibody, a TMB-based method was performed as described before. 
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The results were detected by a microplate reader (Bio Tek, Winooski, VT) at the 
absorbance at 450 nm.  
2.18 Telomere length evaluation 
The length of telomere was determined by Flow-Fluorescence in situ hybridization (Fish). 
The telomere specific FITC-PNA probe (FITC-O O C C C T A A C C C T A A C C C T 
A A O O ) was synthesized by Bio-Synthesis Inc. (Lewisville, TX). The colonocytes 
were isolated from animals as described before (Abolhassani et al., 2008). 106 cells were 
washed by 1 X PBS with 0.1% BSA and centrifuged at 1000 rpm for 7 minutes. Then, 
cells were resuspended in a hybridization buffer (70% Formamide, 1% BSA and 0.02 M 
Tris pH=7.4 ) with or without 0.3 µg/ml Telomere FITC-PCNA probe. For probe 
hybridization, cells were denatured first at 86 °C for 10 minutes. The following 
hybridization was performed at room temperature for 2 hours. The hybridized cells were 
serially washed with Wash I (70% formamide, 0.1% BSA, 0.02 M Tris pH=7.4 and 0.1% 
Tween-20) and Wash II (1 X PBS, 0.1% BSA and 0.1% Tween-20) buffers. The washed 
cells were resuspended in Staining solution (1 X PBS, 0.1% BSA, 10 U/ml RNase A and 
0.6 µg/ml 7-Aminoactinomycin D) for flow cytometric analysis. The signals were 
obtained from both 530/30 nm FITC channel and Blue 670 nm LP channel to evaluate the 
telomere length in live cells.  
2.19 Statistical analysis 
The software, SigmaPlot 12.5 was used for the following statistical analyses. The student 
t-test was employed for analyses of SelH knockdown efficiency (Fig. 3.1B), the growth 
of shRNA MRC-5 cells (Fig. 3.2A, B, E and F; 3.6A; 3.7A), autofluorescence (Fig 
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3.2C), ROS (Fig. 3.2G), glutathione (Fig 3.8A) and apoptosis (Fig. 3.8B) in shRNA cells, 
senescence in shRNA cells (Fig 3.2D; 3.3C; 3.6D; 3.7B), γH2AX and pATM Ser-1981 
positive cells (Fig. 3.3A and B; 3.6B and C), cologenic analysis (Fig. 3.4A, B, C, D and 
E; 3.5; 3.8C), the foci number between SelH/p53 shRNA and SelH/scrambled shRNA 
(Fig. 3.6E), pNrf2 expression (Fig. 3.9A and B), scores of skin abnormality (Fig. 4.1A 
and B), wound healing (Fig. 4.1C), the fluorescence analysis of telomere Flow-FISH 
(Fig. 4.1D), glucose tolerance test (Fig. 4.2C, D, E and F), food intake (Fig. 4.2B), 
insulin tolerance test (Fig. 4.2G and H) and the amount of plasma insulin (Fig. 4.2I and 
J). The average monthly body weight (Fig. 4.2A) was analyzed by paired t-test. To 
determine the effects of age and dietary selenium, two-way ANOVA was employed for 
analyses of plasma selenium (Table 4.1), chemical factors in plasma (Table 4.2), 
connectivity density in bone (Fig. 4.3B), and qPCR of miRNAs (Fig. 4.4) . In the figures 











Chapter 3: Selenoprotein H suppresses cellular senescence through 
genome maintenance and redox regulation via ATM and p53. 
 
Cellular senescence restricts cell proliferation through permanent withdraw from cell 
cycle and has been implicated in tissue regeneration, aging, and tumorigenesis (Rodier 
and Campisi, 2011). Persistent DNA damage, dysfunctional telomere, and acute 
chromosome conformation change can lead to a senescent stage (Fumagalli et al., 2012; 
Mallette and Ferbeyre, 2007; Takahashi et al., 2006). It is thought that cellular 
senescence prevents oncogenesis (Halazonetis et al., 2008) or promotes tissue 
regeneration in early stage of life (Jun and Lau, 2010), but the accumulation of senescent 
cells contributes to aging and age-related disorders later in life (Dimri et al., 1995; 
Ressler et al., 2006; Voghel et al., 2007; Wang et al., 2009).  
ROS induce the formation of oxidative DNA damage and DNA breaks. If left unrepaired, 
persistent activation of DNA damage response can trigger permanent cell cycle arrest, 
known as stress-induced senescence. This notion of oxidative stress accumulation is 
consistent with that of the free radical theory of aging (Harman, 1960; Hutter et al., 2002). 
Ataxia telangiectasia mutated protein (ATM) appears to be a key DNA damage response 
kinase coordinating checkpoint proteins p53 and p21 (Suzuki et al., 2012) and the 
senescence response. ATM is activated in the response to DNA breaks and oxidative 
stress (Guo et al., 2010; Lee and Paull, 2005) and stabilizes p53 by phosphorylation at 
Serine 15 (Canman et al., 1998). An essential role of ATM and p53 in the senescence 
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response has been reported (Bartkova et al., 2005; Bartkova et al., 2006; Wu et al., 2010; 
Wu et al., 2011).  
Selenium, an essential trace element, is required for the biosynthesis of selenoproteins. In 
mammal, the majority of selenoproteins carry antioxidative functions (Kryukov et al., 
2003; Lu and Holmgren, 2009). Selenium deficiency decreases selenoprotein expression, 
with selenoprotein H (SelH), glutathione peroxidase-1, selenoprotein W and Sep15 being 
the most sensitive selenoproteins to body selenium fluctuations (Kipp et al., 2011; Raines 
and Sunde, 2011; Sunde, 2010). Conditional knockout of selenocysteine tRNA that 
suppresses selenoprotein expression in epidermal cells or osteo-chondroprogenitor cells 
showed age-related disorders including alopecia and bone abnormality (Downey et al., 
2009; Sengupta et al., 2010). These observations are consistent with an estimation linking 
eleven selenoproteins to aging or age-related disorders (McCann and Ames, 2011).  
SelH is a thioredoxin-like protein in the nucleolus exhibiting both antioxidant and 
transactivation functions (Novoselov et al., 2007). Studies of human SelH in HT22 
mouse neuronal cells demonstrated that SelH protects against UVB-induced apoptosis 
and being a transactivator for glutathione biosynthesis by employing forward and reverse 
genetic approaches (Ben Jilani et al., 2007; Mendelev et al., 2011; Mendelev et al., 2009; 
Panee et al., 2007). Although human SelH protects mouse HT22 cells against H2O2 
exposure, the mechanism by which SelH protects against oxidative stress and the 
biological consequences are not clear. Because SelH expression is enriched in the 
nucleoli where has been proposed as a possible stress-sensing center in the nucleus 
(Lewinska et al., 2010; Mayer et al., 2005; Panee et al., 2007), the hypothesis is that SelH 
protects against oxidative stress through genome maintenance and limitation of 
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replicative senescence. To test the hypothesis, the stable SelH shRNA knockdown was 
generated in human normal diploid fibroblast and cancerous cells to evaluate their 
cellular and biochemical responses to various clastogens. The results suggested a new 
role of SelH specifically in the cellular response oxidative stress to suppress replicative 
senescence through genome maintenance via ATM and p53. 
3.1 Essential role of SelH in the inhibition of replicative senescence and oxidative 
stress 
Mouse lung cancer LCC1 cells with transient SelH siRNA knockdown are hypersensitive 
to H2O2 exposure (Novoselov et al., 2007); however, the biological significance of SelH 
is largely unknown. To explore whether SelH plays a role in the replicative lifespan of 
normal human fibroblasts, the SelH shRNA and scrambled shRNA knockdown MRC-5 
cells were generated by lentiviral delivery of shRNA cassettes. The choice of the diploid 
lung MRC-5 fibroblast is based on a previous mouse study showing that SelH expression 
is relatively abundant in the lungs and cultured lung cells (Novoselov et al., 2007). The 
two shRNA sequences were designed for targeting the 3’ end of SelH mRNA. Results 
from real-time quantitative RT-PCR demonstrated >80% knockdown efficiency in both 
SelH shRNA MRC-5 cells (Fig. 3.1A and B). Strikingly, SelH shRNA MRC-5 cells 
proliferated poorly. By passage 4 (35 days after clonal selection), SelH shRNA MRC-5 
cells accumulated non-dividing large cells and completely stopped growth, whereas 
scrambled shRNA MRC-5 cells proliferated exponentially (Fig. 3.2A and B). These 









SelH  5'-GCCAAACTTCAGTCATGATCC-3' 




Figure 3.1 shRNA knockdown sequences and knockdown efficiency in MRC-5 cells 
The Sequences of shRNAs are listed in (A). SelH shRNA knockdown efficiency (B) was 
determined by real-time PCR. Total RNA was isolated by TRIzol (Invitrogen), and 
cDNA was transcribed by AffinityScript Multiple Temperature cDNA Synthesis Kit 
(Agilent Technologies, CA). Real-time PCR was carried out using TaqMan Fast 
Universal PCRMaster Mix (Applied Biosystems, CA) and an ABI Prism 7900 Sequence 
Detection System (Applied Biosystems). Quantification of mRNA levels was performed 
using the delta Ct method as previously described (Wu et al., 2011) (*, p<0.05, compared 
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Figure 3.2 Severe inhibition of proliferation, early onset of cellular senescence and 
oxidative stress in SelH shRNA MRC-5 cells. SelH shRNA and scrambled shRNA 
MRC-5 human diploid fibroblast were seeded (104 cell/well) onto 12-well plates and 
cultured for 35 days in 20% O2 incubator (SelH, (A); SelH2, (B)) or 3% O2 incubator 
(SelH, (E); SelH2, (F)) (n=3), followed by cell counting when approaching confluence. 
Autofluorescence was detected in the cells under fluorescence microscope by using GFP 
channel and bright field (C) (*, p<0.05; **, p<0.01, compared to scrambled shRNA 
MRC-5 cells, n=6). SelH shRNA and scrambled shRNA MRC-5 cells were cultured in 
20% O2 and 3% O2 incubators for xx days, followed by analyses of  SA-β-galactosidase 
activity (D) (*, p<0.05, compared to scrambled shRNA MRC-5 cells; #, p<0.05, 
compared SelH shRNA MRC-5 cells at 20% and 3% O2). The SA-β-galactosidase 
positive cells were presented with their respective mean ± S.E (n=3). The cells were at 
second passage after selection, and were incubated with CM-H2DCFDA (10 µmol/L) for 
15 min at 37°C. Then, the GFP signal was determined by fluorescence microscope. The 
fold difference was means ± S.E (n=6) and representative pictures are shown (G) (*, 




Most normal mammalian cells do not divide indefinitely and undergo replicative 
senescence, a terminal cell cycle arrest towards the end of cellular aging (Campisi and 
d'Adda di Fagagna, 2007; Vijg and Campisi, 2008). It was previously demonstrated that 
old cells presented increased expression of autofluorescence (Wilhelm et al., 2009) and 
old fibroblasts were enlarged and flat in shape (Kuilman et al., 2010). To determine 
whether SelH shRNA MRC-5 cells display early onset of cellular aging, the 
autofluorescence, senescence-associated morphological changes, and the expression of 
SA-β-Gal were assessed in the cells, which are the second passage after clonal selection. 
Evaluated by fluorescence microscopy, the intensity of autofluorescence in GFP channel 
was 7-fold greater in SelH shRNA MRC-5 cells than in scrambled shRNA MRC-5 cells 
(Fig. 3.2C). Moreover, the flattened and enlarged phenotypes in SelH shRNA MRC-5 
fibroblasts are indicative of senescence. Because oxygen tension (20% O2, atmosphere 
level) contributes to replicative senescence in human fibroblasts (Parrinello et al., 2003; 
Poulios et al., 2007), the cells were cultured in 3% (physiological level) and 20% O2 
condition to compare the level of replicative senescence.  Whereas scrambled shRNA 
MRC-5 cells were not apparently SA-β-Gal positive (1.0±0.2 % vs 2.3±0.1%) after 7 
days in 3% or 20% O2 incubator, there were significantly greater (P < 0.05) SA-β-Gal 
positive SelH shRNA MRC-5 cells under the same culture condition (Fig. 3.2D). 
Moreover, there were significantly greater (41.5±2.2 % vs 25.7±1.7 %) SA-β-Gal 
positive SelH shRNA MRC-5 cells when cultured in 20% than in 3% O2 incubator, 
suggesting that SelH plays a critical role in the suppression of replicative senescence in 
association with oxygen tension. Furthermore, culturing cells under ambient O2 level 
(20%) could activate stress-induced senescence (Moussavi-Harami et al., 2004). 
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Consistent with this notion, scrambled shRNA MRC-5 cells proliferated 55-fold greater 
in 3% than in 20% O2 incubator after 5 weeks in culture. Interestingly, the complete 
growth inhibition of SelH shRNA MRC-5 cells under 20% O2 condition can be partially 
rescued when grown in 3% O2 incubator; however, SelH shRNA MRC-5 cells still grew 
~300-fold slower compared to scrambled shRNA MRC-5 cells (Fig. 3.2E and F). To 
determine whether oxidative stress contributes to the observed cellular senescence and 
slow proliferation, the level of H2DCFDA fluorescence was measured. It was found that 
intracellular ROS was 3-fold greater in SelH than in scrambled shRNA MRC-5 cells at 
passage 1 after clonal selection under 20% O2 condition (Fig. 3.2G).   
Altogether, these results suggested that SelH is required for cellular proliferation and the 
suppression of replicative senescence in a manner depending of ROS in human diploid 
fibroblast. Indeed, SelH may function as a critical antioxidant to protect against stress-
induced senescence.   
3.2 SelH knockdown MRC-5 cells display severe genome instability and pronounced 
DNA damage response 
Human diploid fibroblasts maintain the senescence arrest by persistent DNA breaks and 
oxidative DNA damage (Campisi and d'Adda di Fagagna, 2007; Chen et al., 1995), both 
of which can activate the key DNA damage response kinase ATM (Guo et al., 2010; Lee 
and Paull, 2005). To determine a role of SelH in the DNA damage and senescence 
responses to oxidative stress, γH2AX and pATM Ser-1981 expression were assessed in 
SelH shRNA and scrambled shRNA MRC-5 cells after H2O2 treatment.  SelH shRNA 
and scrambled shRNA MRC-5 cells were treated with H2O2 (20 µM) for 1 day, followed 
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by 0-5 days recovery in 20% O2 incubator. The percentage of γH2AX or pATM Ser-1981 
positive cells was greater (P < 0.05) in SelH shRNA than in scrambled shRNA MRC-5 
cells intrinsically and 1 day after H2O2 treatment (Fig. 3.3A and B). The H2O2 treatment 
significantly induced γH2AX and pATM Ser-1981 expression in both SelH shRNA and 
scrambled shRNA cells. To assess a role of SelH in the repair of oxidative DNA damage, 
I followed γH2AX and pATM Ser-1981 expression 0-5 days after recovery from the 
H2O2 treatment. While the percentage of γH2AX and pATM Ser-1981 positive cells 
subsided in the scrambled shRNA MRC-5 cells, these markers were further activated 
during the time course of recovery in SelH shRNA MRC-5 cells. Noticeably, the 
reduction of pATM Ser-1981 expression was complete and faster than γH2AX in 
scrambled shRNA MRC-5 cells during the time course, suggesting that 20 µM is a 
physiological dose of H2O2 in normal MRC-5 cells and the ATM pathway activation 
mainly responds to H2O2 but not DNA breaks in this scenario. Therefore, SelH plays a 
pivotal role in the repair of oxidative DNA damage and the prevention of persistent DNA 
damage.  
Permanent DNA damage and persistent DNA damage response are hallmarks of cellular 
senescence (Di Micco et al., 2008; Rodier et al., 2009). In order to further investigate 
whether permanent DNA damage due to acute oxidative stress contributes to senescence, 
the activity of SA-β-Gal was determined at 5 days after recovery from H2O2 treatment 
(20 µM, 1 day) in SelH shRNA and scrambled shRNA MRC-5 cells cultured in 3% and 
20% oxygen incubators. The percent senescent cells ware increased to 17% and 70% in 
scrambled shRNA and SelH shRNA MRC-5 cells, respectively, under ambient oxygen 
level (Fig. 3.3C). Interestingly, in 3% O2 condition, the percent senescent cells 
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significantly dropped from 70% to 34 % in SelH shRNA MRC-5 cells and from 17% to 2 
% in scrambled shRNA MRC-5 cells. Therefore, SelH appears to suppress cellular 
senescence when persistent DNA damage response is induced by chronic and acute 
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Figure 3.3 Persistent DNA damage response and increased sensitivity to chronic 
oxidative stress in SelH shRNA MRC-5 cells. SelH shRNA and scrambled shRNA 
MRC-5 cells were at second passage after selection, seeded onto coverslip, treated with 
20 µM H2O2 for 24 hours, and followed by 5-day recovery in fresh medium for the 
detection of phosphorylation of H2AX on Ser-139 (γH2AX) and ATM phosphorylation 
on Ser-1981 (pATM Ser-1981). The percentages of γH2AX (A) or pATM Ser-1981 (B) 
positive cells were presented with mean ± S.E (n=6) (*, p<0.05, compared to scrambled 
shRNA MRC-5 cells at individual time point). Detection of SA-β-galactosidase positive 
cells was performed as described in Figure 1, and the data were presented with mean ± 
S.E (n=6) (C) (*, p<0.05, compared to scrambled shRNA MRC-5 cells; #, p<0.05, 






3.3 SelH deficiency specifically sensitizes cells to clastogens that induce oxidative stress 
To address whether SelH protects against clastogens other than H2O2, cells were exposed 
to a variety of genotoxic agents and subjected to colonogenic assay. Although this 
method is considered a gold standard for assessing cell proliferation after DNA damage, 
not all cells, including the MRC-5 diploid fibroblasts, are capable of forming colonies 
from very low density seed cells. To circumvent this limitation and to determine whether 
SelH protection against oxidative DNA damage limits to diploid cells, the SelH shRNA 
and scrambled shRNA HeLa cells were generated by lentiviral delivery. Consistent with 
the results shown in MRC-5 cells, cologenic assay revealed that SelH shRNA HeLa cells 
displayed greater sensitive to oxidative stress inducers, including H2O2 and paraquat (Fig. 
3.4A and B). In contrast, colony formation was comparable between SelH shRNA and 
scrambled shRNA HeLa cells in response to a gradient concentration of replication stress 
inducers hydroxyurea and camptothecin and a potent γ-irradiation mimetic, 
neocarzinostatin (Fig. 3.4C, D and E). In addition, SelH shRNA HCT116+hMLH1 
colorectal cancer cells (Qi et al., 2010) displayed hypersensitivity to H2O2 exposure in a 
dose-dependent manner (Fig. 3.5). Therefore, SelH protects against clastogens specific to 
those induce ROS in various cells. To further investigate the role of SelH in the cellular 
response to DNA damage, the live cell imaging of SelH translocation to the site of 
localized DNA damage containing a mixture of DNA breaks and oxidative DNA damage 
was performed by monitoring fluorescent EGFP-tagged SelH and DsRed-tagged PCNA, 
a sensitive marker of DNA synthesis and repair (Balajee and Geard, 2001; Mortusewicz 
et al., 2011). Although PCNA was recruited to and enriched at the site of DNA damage, 
SelH did not mobilize to the site of DNA damage (Fig. 3.4F). Therefore, SelH 
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specifically protects against oxidative stress, but this is less likely to be directly involved 
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Figure 3.4 Increased sensitivity of SelH shRNA HeLa cells to H2O2 and paraquat 
but not other clastogens.  Colony forming assay was performed in SelH shRNA and 
scrambled shRNA HeLa cells after treated with a gradient concentration of  H2O2 (A), 
Paraquate (B), Hydroxyurea (C), Neocarzinostatin (D) and Camptothecin (E). The 
survival rates were presented with mean±S.E. (n=3) (*, p<0.05; **, p<0.01, compared to 
SelH shRNA HeLa cells). Localized DNA damage was generated in SelH-GFP and 
PCNA-DsRed overexpression MRC-5 cells. The localizations of SelH and PCNA were 













Figure 3.5 Increased sensitivity of SelH shRNA HCT116 complimented cells to H2O2 
and paraquat but not other clastogens. Colony forming assay was performed in SelH 
shRNA and scrambled shRNA HCT116 complimented cells after treated with a gradient 
concentration of  H2O2. The survival rates were presented with mean±S.E. (n=3) ( **, 













3.4 The slow proliferation phenotype in SelH shRNA MRC-5 cells is rescued by the 
inhibition of ATM kinase or p53 shRNA knockdown 
Both the ATM kinase and p53 are involved in the senescence response to oxidative stress 
in MRC-5 and endothelial cells (Wu et al., 2010; Zhan et al., 2010). Thus, the SelH and 
scrambled shRNA MRC-5 cells were treated with a specific ATM kinase inhibitor, Ku 
60019 (5 µM, (Golding et al., 2009)), in a 20% O2 incubator during the 28 days time 
course. Interestingly, Ku 60019 treatment rescued the inhibition of proliferation in SelH 
shRNA MRC-5 cells and resulted in a 3-fold increase in proliferation on Day 28. 
However, scrambled shRNA MRC-5 cells didn't proliferate faster in the presence of Ku 
60019 (Fig. 3.6A). At day 28, the fold difference of cell number between scrambled 
shRNA and SelH shRNA MRC-5 cells is 14 fold in complete medium, but the fold 
difference of cell number was decreased to 3.6 fold with Ku 60019 treatment. After 28 
days in 20% O2 incubator, the induction of γH2AX and pATM Ser-1981 expression in 
SelH shRNA MRC-5 cells was suppressed in the presence of Ku 60019 (Fig. 3.6B and 
C), suggesting that the ATM kinase is responsible for the DNA break response of SelH 
shRNA MRC-5 cells to chronic oxidative stress. Because Ku 60019 treatment reversed 
γH2AX expression to the level of Day 0 but suppressed pATM Ser-1981 expression to a 
much lower extent compared to Day 0, these results suggest that kinases other than ATM 
accounts for the basal H2AX phosphorylation on Day 0 and γH2AX induction after 28 
days exposure of the cells in 20% O2 incubator is ATM-dependent. Analyses of SA-β-
Gal staining confirmed that the ATM kinase is required for SelH shRNA cells to be 
senescent (40% vs. 5%) after being exposed to 20% O2 for 28 days (Fig. 3.6D). Similar 
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proliferation and senescence results were observed when the cells were treated with Ku 
55933, a popular but less specific ATM kinase inhibitor (Fig. 3.7A and B).   
To further explore whether the role of SelH in the suppression of replicative senescence 
is mediated through p53, the SelH and p53 double knockdown was tested in MRC-5 cells. 
After puromycin selection, there were 6-fold greater foci in SelH and p53 double shRNA 
than in SelH shRNA MRC-5 cells (Fig. 3.6E). In particular, the cell size was much 
smaller and rounded in the SelH and p53 double shRNA MRC-5 cells, as opposed to the 
enlarged and flattened SelH shRNA cells, under a 40-fold light microscope (Fig. 3.6F). 
Altogether, the ATM kinase and p53 are necessary for the replicative senescence 
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Figure 3.6 The kinase activity of ATM and p53 are involved in the protection of 
SelH against replicative senescence in MRC-5 cells.  SelH shRNA and scrambled 
shRNA MRC-5 cells were seeded in 12-well plates (2 x 104 cells/well) and co-treated 
with or without 5 mM Ku60019 for 28 days, followed by cell counting (A). 
Immunofluorescent analyses of γH2AX (B) and pATM Ser-1981 (C) (*, p<0.05, 
compared to Day 0; #, p<0.05, compared to Day 28 without Ku 60019 treatment), and 
SA-β-galactosidase positive cells (D) (*, p<0.05, compared to Day 28 without Ku 60019 
treatment) were detected in SelH shRNA MRC-5 cells. These assays were performed as 
described in Figures 1 and 2. SelH shRNA MRC-5 cells were infected with p53 shRNA 
or scrambled shRNA lentiviral particles, followed by puromycin selection for 14 days. 
The viable foci were counted after crystal violet staining. A focus is defined as one 
containing at least 50 cells. Values are means ± S.E. (n=3) (*, p<0.05, compared to SelH 
shRNA only MRC-5 cells) (E). Representative pictures under 40 fold bright field 
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Figure 3.7 The kinase activity of ATM and p53 are involved in the protection of 
SelH against replicative senescence in MRC-5 cells.  SelH shRNA and scrambled 
shRNA MRC-5 cells were seeded in 12-well plates (2 x 104 cells/well) and co-treated 
with or without 5 mM Ku55933 for 28 days, followed by cell counting (A) and SA-β-
galactosidase positive cells (B). These assays were performed as described in Figures 1 












3.5 The role of transactivation on phase II antioxidant is required to protect cells 
against oxidative damages 
It was proposed previously that SelH overexpression may transactivate the expression of 
a key gene for glutathione biosynthesis (Panee et al., 2007). Consistent with this notion, 
here the data showed that SelH shRNA HeLa cells expressed significantly less (P < 0.05) 
glutathione before and after H2O2 exposure for 24 hours (Fig. 3.8A).  H2O2 treatment 
(20-80 µM) induced linearly increased glutathione levels in both SelH and scrambled 
shRNA HeLa cells. At the concentration of H2O2 at 320 µM, glutathione was almost 
completely depleted in SelH shRNA cells, resulting in a 17.5-fold difference as compared 
to scrambled shRNA HeLa cells. Therefore, SelH shRNA cells are defective in  
maintaining intracellular glutathione. To test the hypothesis that decreased glutathione 
sensitizes SelH shRNA cells to oxidative stress and limits cell proliferation, the SelH 
shRNA and scrambled shRNA HeLa cells were treated with H2O2 at 160 µM for 0-24 
hours and assessed apoptotic cell death by using mitocapture. The apoptotic SelH shRNA 
and scrambled shRNA HeLa cells increased linearly 0-12 hours after H2O2 treatment (Fig. 
3.8B). There were approximately 80% and 20-30% apoptotic SelH shRNA and 
scrambled shRNA HeLa cells, respectively, 12 and 24 hours after H2O2 treatment. Further 
statistical analyses showed that glutathione levels were inversely associated with 
apoptotic death on a certain H2O2 concentration. Therefore, SelH may keep glutathione 
level on check under oxidative stress and prevent apoptotic cell death. To test whether 
intracellular glutathione maintains cell survival under oxidative stress, colonogenic assay 
was performed by treating the cells with H2O2 in the presence or absence of a glutathione 
mimic agent, N-acetylcysteine (NAC). The supplement of NAC (10 mM) rescued the 
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proliferation of SelH shRNA HeLa cells to a level similar to that of the scrambled 
shRNA HeLa cells (Fig. 3.8C). These results suggest that SelH may counteract oxidative 
stress and maintain cell proliferation through maintenance of intracellular glutathione 
level. 
It has been reported that the Nrf2-Keap1 pathway also regulates glutathione biosynthesis 
(Moinova and Mulcahy, 1999). Upon increased oxidative stress, phosphorylated Nrf2 
disassociates from Keap1 and accumulates in the nucleus for assisting the expression of 
phase two antioxidants, including glutathione. To test whether the Nrf2-Keap1 pathway 
is differentially activated in SelH and scrambled shRNA cells after oxidative stress, 
Western analyses was used to determine the accumulation of phosphorylated Nrf2 in the 
nuclear fractions after treatment with a gradient concentration of H2O2 (Fig. 3.9A).  There 
was significant greater phosphorylated Nrf2 in the nucleus of SelH shRNA HeLa cells 
than in scrambled shRNA HeLa cells. After H2O2 treatment, there was a dose-dependent 
increase in nuclear pNrf2 in both SelH shRNA and scrambled shRNA HeLa cells, but the 
extent of which is greater in the former than the latter cells. The same is true in MRC-5 


















Figure 3.8 Intracellular glutathione is involved in the protection of SelH against 
oxidative stress.  SelH shRNA and scrambled shRNA HeLa cells were cultured in 10-cm 
dishes and treated with H2O2 (0-320 µM) for 24 hours, followed by staining of isolated 
single cells with monochlorobimane for flow cytometric analysis (A) (*, p<0.05, 
compared to Scrambled shRNA HeLa cells). Some cells were treated with H2O2 at 160 
µM for 0-24 hours and harvested for mitocapture staining to determine apoptotic cells. 
The percentapoptotic cells were presented with mean ± S.E. (n=8) (*, p<0.05, compared 
to Scrambled shRNA HeLa cells), and representative pictures were shown (B). Colony 
forming assay was performed in SelH shRNA and scrambled shRNA HeLa cells treated 
with H2O2 (0, 15 and 20 µM) alone or together with N-acetylcystine (NAC, 10 mM). The 
number of colonies in scrambled shRNA cells without H2O2 or NAC treatment was set as 


























Figure 3.9 Accumulation of phosphorylated Nrf2 in the nucleus of scrambled 
shRNA and SelH shRNA HeLa or MRC-5 cells. SelH shRNA and scrambled shRNA 
HeLa cells were cultured in 15-cm dishes and treated with H2O2 (0-80 µM) for 24 hours. 
The nuclear fraction of HeLa cells were applied for immunoblotting analysis by using 
anti-phospho-Nrf2 (pNrf2) and anti-Lamin B antibodies. The intensity was quantified by 
ImageJ and presented with means ± S.E. (n=3) (A) (*, p<0.05, compared to Scrambled 
shRNA HeLa cells). SelH shRNA and scrambled shRNA MRC-5 cells were seeded onto 
coverslip, treated with H2O2 (20 µM) for 24 hours, followed by 5-day recovery in fresh 
medium. (B) The percentage of nucleus-specific pNrf2 was presented with means ± S.E. 








In this study, the evidence indicated that the role of SelH in human diploid cells is 
protecting cells against genome instability and early onset replicative senescence through 
the clearance of ROS. The antioxidation activity of SelH had been demonstrated 
previously that the transient SelH siRNA knockdown mouse cells were more sensitive to 
increased oxidative stress, and human SelH overexpression in murine hippocampal HT22 
cells strengthened the antioxidative function (Novoselov et al., 2007; Panee et al., 2007). 
However, the previous studies used immortalized cells to study the function of SelH, but 
the biological significance of SelH in mortal cells is still largely unknown. The results 
showed that SelH was required in human diploid fibroblast to prevent the early inhibition 
on proliferation in physiological or atmosphere level of oxygen or increased oxidative 
stress. The absence of SelH in MRC-5 cells promoted the accumulation of ROS robustly, 
and it leaded to induce higher level of DNA damage and DNA damage response, which 
activated replicative senescence. Additionally, the sub-lethal dose of H2O2 treatment 
further generated permanent DNA damages and persistent DNA damages response to 
activate severe replicative senescence in SelH knockdown MRC-5 cells, so SelH is 
required for the protection from chronically-increased oxidative stress induced genome 
instability and replicative senescence. In the mean time, ATM and p53 are necessary 
components in SelH deficient activated replicative senescence. According to the previous 
evidence, SelH was proposed to play a role as transcription factor (Panee et al., 2007), 
which facilitates GSH biosynthesis. Thus, the data indicated that SelH was required for 
maintaining the level of intracellular GSH, especially with the increased level of 
oxidative stress, and this function is critical for SelH to protect cells from oxidative stress 
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induced damages. Finally, SelH desensitized Nrf2 pathway activation, so the role of SelH 
is at the front line of antioxidation. Here, the data suggests that SelH has a new role on 
maintaining genome stability and suppressing replicative senescence as an antioxidant 
and transactivator in human diploid fibroblast (Figure 3.10).  
Permanent DNA damage and persistent DNA damage response both activate replicative 
senescence (Campisi and d'Adda di Fagagna, 2007). ROS is an endogenous and 
continuous damaging source to dampen genome stability. However, the accumulation of 
ROS in the cell is a general trend of cellular and organismal aging (Harman, 1960; 
Lawless et al., 2012) because of the reduction of antioxidant capacity (Kim et al., 2002b; 
Kimoto-Kinoshita et al., 1999; Perez et al., 1991; Pieri et al., 2001; Sivonova et al., 2007; 
Williams et al., 2008) or the increase of ROS production. Hence, when the sub-lethal 
dose of H2O2 was used to mimic the chronic increase of oxidative stress, the permanent 
DNA damages and persistent DNA damage response presented in SelH knockdown 
MRC-5 cells but not in scrambled shRNA MRC-5 cells. The possible explanation is that 
SelH deficiency in human diploid fibroblast may already establish the prone of genome 
instability in the cell. Prior to the treatment with sub-lethal doses of H2O2, the SelH 
deficient cells, which are at second passage after clonal selection, already had higher 
level of DNA breaks and DNA damage response. SelH deficient condition may 
chronically result in genome instability, so the chronic oxidative stress treatment may 
further generate severe DNA lesions on unstable genome to activate senescence through 
unrepaired DNA damage and persistent DNA damage response. Noteworthy, during SelH 
shRNA knockdown clonal selection, the number of viable colonies of SelH shRNA 
MRC-5 cells in 3% O2 was 3 fold more than in 20% O2 (Data not shown). The evidence 
89	  
	  
supported the idea that SelH deficiency may chronically damage cells, so 20% O2, the 
chronic oxidative stress, lowered the number of viable clones.  
SelH is a possible redox sensor to control the homeostasis of oxidative stress in the cell. 
Previously, nucleolar, where transcription of rRNA takes place, has been proposed to be 
the redox sensor in the cell. The rRNA transcription is halted when there is an acute and 
severe increase of oxidative stress sensed by nucleolar (Lewinska et al., 2010). The action 
also halts the protein translation until the cell surpasses the stress (Mayer et al., 2005). 
Interestingly, SelH was found to localize to nucleoli specifically with critical role on 
antioxidation and facilitating GSH biosynthesis (Novoselov et al., 2007; Panee et al., 
2007). In the scrambled shRNA HeLa cells, the level of intracellular GSH was gradually 
increased with the gradient increased H2O2 treatment. Differently, the level of GSH in 
SelH shRNA HeLa cells was only induced from 0~80 µM H2O2, but started to drop 
sharply from 160 µM H2O2 and depleted at 320 µM H2O2. Although the level of GSH is 
still inducible by low dose of H2O2 in the SelH deficient condition, the induction of GSH 
production may be regulated solely by Nrf2, which is one of the transcription factors to 
promote GSH biosynthesis (Suh et al., 2004). On the other hand, the results showed that 
the accumulation of pNrf2 in nucleus fraction was less in the gradient H2O2 treatment in 
scrambled shRNA MRC-5 and HeLa cells, whereas pNrf2 was accumulated robustly in 
SelH shRNA MRC-5 and HeLa cells. The data suggested that the synergistic regulation 
by both SelH and pNrf2 is critical to maintain the homeostasis of oxidative stress and cell 
survival, and the accumulation of pNrf2 in the nucleus is less sensitive when the cells 
have functional SelH. Noteworthy, the evidence from Burk et al. suggested that selenium 
deficiency leaded to pNrf2 accumulation in nuclei in mouse liver, but the other natural 
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antioxidant, Vitamin E, deficiency didn't promote the same action (Burk et al., 2008). 
Then, pNrf2 may transactivate phase II antioxidant in the nucleus, including some 
selenoproteins (Burk et al., 2008; Singh et al., 2006). Since SelH is one of the most 
dietary selenium sensitive selenoproteins, the dietary selenium deprivation may lead to 
SelH deficiency. Thus, the increased pNrf2 accumulation may be resulted from SelH 
deficiency in dietary selenium deficiency. According to the available lines of evidence 
and the results here, SelH might be a possible redox sensor to control the activation of 
cellular defense system on oxidative stress, i.e. Keap1-Nrf2 pathway for transactivating 
phase II antioxidants.     
The SelH deficient MRC-5 cells showed early onset cellular aging, which may sensitize 
the cells to DNA damage. Based on the phenotypic observation, the cellular aging 
phenotypes, morphological change, increased autofluorescence and increased level of 
ROS, were found in SelH knockdown MRC-5 cells. The capacity of DNA repair has been 
proposed to be decreased with age (Garm et al., 2013), especially DNA DSB repair. Thus, 
increased genome instability in SelH knockdown MRC-5 cells might be resulted from 
impaired DNA repair mechanism, because the molecular age of the cell is older than 
scrambled shRNA MRC-5 cells. Additionally, the older cells promotes the production of 
ROS, which exacerbates genome instability. Although the activation of replicative 
senescence plays positive role on anti-tumorigenesis in premalignant cells (Bartek et al., 
2007), it is also critical to accelerate aging and age-related disorders in normal cells 
(Wang et al., 2009). The data suggested that SelH plays a key role to prevent advanced 
molecular age of the cell which may lead to sever genome instability through impaired 
DNA repair mechanism and increased level of ROS. 
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Herein, there is a proposed new role of SelH to protect human normal diploid cells 
against early onset replicative senescence. In the nucleus, SelH prevents the chronic 
oxidative stress induced DNA damages, which may activate DNA damage response and 
cellular senescence by ATM and p53, respectively. Moreover, SelH also serves as a 
transcription factor to activate glutathione, and the increased level of glutathione may 
further reinforce the antioxidation function to prevent oxidative DNA damages (Figure 
3.10). To sum up, SelH serves as a oxidative stress sensor to regulate the homeostasis of 
oxidative stress in nucleus to prevent severe DNA damages induced senescence. 
Previously, 11 out of 25 selenoproteins were predicted to be related to aging (McCann 
and Ames, 2011). Additionally, the selenocysteine tRNA[Ser]Sec gene (Trsp) conditional 
knockout in epidermal cells (Sengupta et al., 2010) and osteo-chondroprogenitor cells 
(Downey et al., 2009) showed premature aging phenotypes. The conditional knockout 
generated selenoprotein deficient condition, which is also possibly created by dietary 
selenium deficiency. Interestingly, selenoprotein H is one of the most dietary selenium 
sensitive selenoprotein (Kipp et al., 2009; Sunde, 2010). Although SelH is not in the list 
of aging-related selenoproteins (McCann and Ames, 2011), the observed replicative 
senescence in SelH knockdown human diploid cells suggested SelH is a new aging-
related selenoprotein needed for the protection against chronic oxidative stress induced 








Figure 3.10 Proposed function of SelH in cellular senescence SelH is a dual function 
protein localized specifically in nucleolus. Firstly, SelH serves as antioxidant in nucleus 
to suppress ROS induced genome instability, which may activate senescence through 
ATM and p53. Secondly, SelH may transactivate glutamate cysteine ligase transcription 
to facilitate glutathione biosynthesis. This is critical for cells to protect against oxidative 
damage. Lastly, SelH regulates the homeostasis of oxidative stress in the nucleolus to 
control the accumulation of pNrf2 in the nucleus, which represents the activation of 







Chapter 4: Essential role of selenium at nutritional levels of intake in 
mouse health span and lifespan 
To better model human health span and lifespan in the mouse model, Terc-/- (telomerase 
RNA component) (Blasco et al., 1997) and Tert-/- mice (Yuan et al., 1999) carrying 
humanized telomeres are generated. Since the identification of Hayflick limit and 
telomere, telomere became one of the critical determinants of lifespan, which protects 
chromosome end against natural telomere attrition (Greider, 1998; Harley et al., 1990; 
Linskens et al., 1995). The length of telomere is highly correlated to the lifespan and 
health span of human aging (Barbieri et al., 2009; Honig et al., 2012; Kong et al., 2013). 
However, telomeric repeats in human cells average between 10 and 15 kb in length. In 
contrast, the laboratory mouse species Mus musculus possesses much longer telomeres, 
ranging in size from 40 to 80 kb (Blasco et al., 1997; Zijlmans et al., 1997). Furthermore, 
telomerase activity is absent in most human somatic cells, while low levels of telomerase 
activity are present in mouse somatic cells to attenuate telomere attrition. Since mouse 
telomeres are much longer than those of humans and telomerase activity is detectable in 
mouse somatic cells, replicative senescence is unlikely to occur during the normal aging 
process in mice. These telomerase-deficient mice are viable, fertile and have no 
significant physiological abnormalities at early generations. Progressive inbreeding of 
Terc-/- mice is required to gradually shorten telomere length to a range reminiscent of that 
in humans (Blasco et al., 1997). Rudolph et al (Rudolph et al., 1999) showed that 
generation 3(G3) Terc-/- mice display skin ulceration, alopecia and hair graying, but not 
many other disorders in association with human aging, including osteoporosis, body 
weight changes, shortened lifespan, and type II diabetes (Rudolph et al., 1999).  The 




Selenium is required not only for optimal health span but lifespan potentially. As an 
essential trace element, selenium has a U-shaped relationship with risk of diseases 
(Fairweather-Tait et al., 2011). The level of dietary selenium regulates the expression of 
selenoproteins (Burk and Hill, 1993), which play important roles in the body on 
antioxidation, redox signaling, thyroid hormone maturation, protein folding in ER and 
even more unknown functions required to be discovered (Papp et al., 2007). While recent 
research has demonstrated that mice have selenoprotein deficiency by selenocysteine 
tRNA knockout specifically in epidermal cells (Sengupta et al., 2010) or in osteo-
chondroprogenitor cells (Downey et al., 2009) showed an apparently aging phenotype 
characterized by alopecia and bone abnormality. Of the 25 mammalian selenoproteins, 11 
are believed to have functional roles related to aging (McCann and Ames, 2011); 
however, it is not clear whether Selenium, particularly, at nutritional levels of intake, may 
play a role in aging and age-related disorders.   
Telomere attrition provokes DNA damage and, subsequently, replicative senescence 
(d'Adda di Fagagna et al., 2003). Because the chromosomes of mice carry longer 
telomeres than those of humans (Blasco et al., 1997), the aging phenotypes of such 
premature aging syndromes in humans as Werner syndrome and ataxia-telangiectasia do 
not appear in mice when only the responsible mutated genes (Wrn and Atm) have been 
knocked out.  However, those aging phenotypes of Wrn-/- and Atm-/- mice can be 
recapitulated under a short telomere background (Chang et al., 2004; Wong et al., 2003). 
Similarly, mice unable to express the major selenoprotein, glutathione peroxidase-1, 
develop normally and are apparently healthy up to 20 months of age (Ho et al., 1997). 
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Clearly, what is lacking is an appropriate aging model of dietary Se deficiency displaying 
many features of normal aging. The hypothesis is that lengthy telomeres preclude mice 
deprived of Se to display aging phenotypes and age-related disorders. Closing this 
knowledge gap is critical to advance understanding of the health roles of dietary Se.  
4.1 Dietary selenium deprivation causes early onset of aging phenotypes in short 
telomere mice  
It had been proposed that there are 11 selenoproteins are related to aging and age-related 
disorders, but the expression of selenoproteins are highly correlated with dietary selenium. 
To dissect a specific role of dietary Se in age-related dysfunction, the short telomere G3 
Terc-/- mice were employed as the animal model. The length of telomere is a key factor 
for human organismal aging, so the proper animal model, late generation Terc-/- mice, is a 
well-developed model to study human organismal aging with human aging phenotypes, 
such as hair graying, alopecia, weak wound healing (Rudolph et al., 1999).  The short 
telomere mice were prepared from Se-adequate G1 Terc-/- following mating scheme (Fig. 
2.1), and fed after weaning with a purified basal diet (<0.03 ppm of Se by analysis) or the 
diet supplemented with sodium selenate (0.15 ppm) throughout their life. The level of 
plasma Se concentrations were significantly reduced (P < 0.001) by dietary Se 
deprivation (ng/mL; Se-deficient mice: 9 mo, 156 ± 10; 18 mo, 131 ± 18; Se-adequate 
mice: 9 mo, 372 ± 16; 18 mo, 394 ± 14, n = 5/group) (Table 4.1), but the reduction is not 
related to the effect of aging. Following the continuous observation, the age-related 
appearance change happened earlier and severer in animals with selenium deprivation 
than the animals with selenium supplementation. Deprivation of body Se accelerated the 
skin abnormality in male G3 Terc-/- mice starting at 7 months of age but not until 10 
96	  
	  
months in G2 Se-deficient Terc-/- mice (not shown), further supporting the hypothesis that 
long telomere limits Se-deficient mice to reveal aging phenotypes. The alopecia (scored 
4+) was greatly accelerated by dietary Se deprivation in the male G3 Terc-/- mice (Se-
deficient, 29/73 vs. Se-adequate, 8/84, P < 0.05, Fig. 4.1A). The average scores of skin 
abnormity were consistently higher in selenium deficient short telomere animals at 
different age (Fig. 4.1B). On the other hand, loss of the ability on wound healing is one 
of the age-related disorders for normal human aging, so the skin surgery was performed 
to test the ability of wound healing in both animals in selenium deprived or supplemented 
diets. During the all 7-day recovery, the animals in selenium deprived diet significantly 
kept continuously greater wound area (n=5, p<0.05) than the animals in selenium 
supplemented diet. At day 7, in 12 and 18 month-old mice, the average size of the 
wounds was found to be decreased to 7.2 % and 16.4 % of the original wound in Se-
adequate mice, but it was only decreased to 21.6 % and 40.6 % in Se-adequate mice (Fig. 
4.1C). The data suggested that the Se-deficient late generation Terc-/- mice showed skin 
abnormality, an aging phenotype, significantly earlier than the animals in Se-adequate 
diet. Furthermore, the flow FISH method was performed by a FITC-labeled (CCCTAA)3 
PNA probe as described in Rudolph et al (Rudolph et al., 1999). The Flow-FISH 
telomere analysis by using primary colonocytes isolated from G3 Terc-/- mice at 18 
months of age showed that Se deprivation shortened average telomere length by 25% 
(Fig. 4.1D). 
Therefore, there was a very interesting model of aging established by deprivation of Se in 
short telomere Terc-/- mice that displays many hallmarks of human aging and can reveal 
the roles of Se at nutritional levels, in contrast with previous approaches in which this 
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Table 4.1 Plasma selenium levels in the mice with Se-deficient or Se-adequate diets 
at younger than 12 months or than 18 months of age. The effects of age and dietary 
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Figure 4.1 Se-deficient G3 Terc -/- mice had early onset of aging phenotypes and 
faster telomere attrition. The scores of hair graying and skin abnormality were recorded 
in different age, and the references for scoring hair graying and skin abnormality were 
also showed here (A). The average scores of hair graying and skin abnormality were 
showed in different ages (*, p<0.05, compared to Se-deficient mice) (B). The wound 
healing experiment was performed on Se-deficient and Se-adequate mice at age of 12 
months or 18 months. The wound was generated by 5-mm biopsy, and the size of the 
wound was measured in the following 7 days. The representative pictures were listed. (*, 
p<0.05; **, p<0.01, compared to Se-adequate mice) (C). The length of telomere was 
measured by Flow-FISH. The isolated colonocytes from 24 month-old mice were 
subjected to perform FISH with FITC-telomere-PNA probe, which was used to hybridize 
with telomere. The stronger FITC intensity represents longer telomere with more FITC-




4.2 Dietary selenium deprivation causes age-related abnormities in Short telomere 
mice 
Markers for the alteration of health span 
In humans, aging is associated with numerous pathophysiological conditions including 
increased glucose and body weight leading to diabetes and cardiovascular disease. The 
role of Se in diabetes is complicated and awaits further investigation. These Se-deficient 
G3 Terc-/- mice had alterations in plasma levels of markers that predict the onset of 
diabetes, liver damages and muscular dysfunction, including blood glucose and lactate 
dehydrogenase (Table 4.1). These plasma markers were measured by AniLytics Inc. 
(Gaithersburg, MD) as described previously (Baur et al., 2006). Plasma glucose level was 
greater in fasting Se-deficient than Se-adequate G3 Terc-/- mice at both 12 and 18 months 
of age, and was lowered in 18 than 12 months of age. Plasma lactate dehydrogenase 
activity was greater in fasting Se-deficient than Se-adequate G3 Terc-/- mice at 12 but not 
18 months of age. Plasma amylase activity or albumin level was not affected by dietary 











Table 4.2 Chemical factors in Se-deficient and Se-adequate mice at the age of 12 




Based on the analysis of plasma markers, the fasting blood glucose in Se-deficient G3 
Terc-/- mice was higher than Se-adequate G3 Terc-/- mice at both 12 and 18 months of age. 
Additionally, Se-deficient G3 Terc-/- mice have significantly heavier average body weight 
than Se-adequate G3 Terc-/- mice between 13 and 18 months of age. (Fig. 4.2A), but there 
was no significant difference on weekly food intake either at younger than 6 months or 
between 6 to 12 months of age (Fig. 4.2B). These results suggested defective glucose 
regulation in Se-deficient G3 Terc-/- mice. To explore this further, the glucose tolerance 
test, insulin tolerance test were performed, and the level of plasma insulin was 
determined during glucose tolerance test. The result of glucose tolerance test indicated 
glucose tolerance was similar in Se-deficient and Se-adequate G3 Terc-/- mice at 9 month-
old (Fig. 4.2C). However, Se-deficient G3 Terc-/- mice had gradually developed glucose 
intolerance at both 12 and 18 month-old, and the symptom was aggravated as the mice 
age (Fig. 4.2E and F). Interestingly, the glucose intolerance symptom didn't exist in 
either Se-deficient or Se-adequate G1 Terc+/+ mice (Fig. 4.2C). On the other hand, the 
onset of diabetes is usually preceded by insulin resistance. To test if Se deficiency affects 
insulin sensitivity during the aging process, the whole-body insulin sensitivity test was 
performed by insulin tolerance test (0.25 U/kg body weight, i.p. injection). The Se-
deficient mice demonstrated insulin resistance compared with Se-adequate G3 Terc-/- 
mice at both 12 and 18 months of age. After the insulin injection, the reductions of 
whole-blood glucose, relative to their initial levels, were ~30% less (P < 0.05) in the Se-
deficient than in the Se-adequate mice during the time course (Fig. 4.2G and H). To 
determine whether glucose intolerance in the Se-deficient mice was affected by blood 
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insulin level, the plasma insulin concentrations were determined in glucose tolerance test 
(as described in Fig. 4.2) by using a mouse insulin ELISA kit (Alpco Diagnostics, 
Windham, NH). At 12 months of age, plasma insulin level was lower in Se-deficient than 
in Se-adequate G3 Terc-/- mice after glucose injection (Fig. 4.2I). Strikingly, glucose 
administration did not elicit the elevation of plasma insulin in Se-deficient G3 Terc-/- 
mice at 18 months of age, although there was clearly an age-dependent decline in the 
insulin induction upon glucose administration in Se-adequate G3 Terc-/- mice (Fig. 4.2J). 
Altogether, these results strongly suggest that dietary Se deficiency deteriorated both 
insulin sensitivity on peripheral cells and insulin production in the pancreas, resulting in 
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Figure 4.2 Gradually developed glucose metabolism disorder in Se-deficient mice 
The monthly average body weights of Se-deficient and Se-adequate mice (A). The 
weekly food consumption of the mice in Se-deficient or Se-adequate diets at younger 
than 6 months or between 6 to 12 months of age (B). Glucose tolerance test was 
performed in Se-deficient and Se-adequate G1 Terc+/+ mice at 12 months of age (C), G3 
Terc-/- mice at 9 (D), 12 (E) or 18 (F) months of age. Mice were fasted 8 hours prior to 
start the test. Glucose was injected by i.p. (1 µg/Kg), and blood glucose was measured by 
glucose meter in every 30 minutes till 2.5 hours after injection. Insulin tolerance test was 
performed in Se-deficient and Se-adequate G3 Terc-/- mice at age of 12 (G) or 18 (H) 
months. Insulin was injected by i.p. (0.75 units/Kg), and blood glucose was measured by 
glucose meter in every 30 minutes till 2.5 hours after injection. Plasma insulin was 
determined by insulin ELISA kit in Se-deficient and Se-adequate G3 Terc-/- mice at age 
of 12 (I) or 18 (J) months. The plasma was collected at each time point in the glucose 





Losing the integrity of bone is a classic age-related disorder (Pietschmann et al., 2009). 
Interestingly, dietary selenium was found to play an important role in bone integrity as 
evidenced by mouse studies fed with a Se-deficient diet for 4 months (Cao et al., 2012) or 
with Trsp (the gene coded for selenocysteine tRNA) conditional knockout in osteo-
chondroprogenitors (Downey et al., 2009) and by human epidemiological studies 
(Suetens et al., 2001). However, how Se deficiency affects bone integrity later in health 
span is not known. To explore the alterations of bone integrity in terms of selenium status 
and aging, in each group, 5 femoral bones per group had been analyzed by µCT scanning. 
The data showed that the connectivity density was decreased by dietary Se deficiency, the 
extent of which was significantly greater in mice at 18 months (51%) than in 12 months 
(22%) of age (Figure 4.3A and B). Although changes of all other femoral bone structural 
indices are not statistically significant, the number of trabecular fiber and separation 
appeared to be decreased and increased, respectively. Altogether, these results suggest a 
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Figure 4.3 Bone integrity decreased dramatically in Se-deficient mice. The femoral 
bones were collected from Se-deficient and Se-adequate mice at age of 12 or 18 months, 
and subjected to detect by µCT scanning. The representative reconstitutive bone structure 
is showed in (A). The connectivity density of Se-deficient and Se-adequate mice at age of 




4.3 Identification of circulating miRNA signature by openarray and qPCR analyses in 
Se-deficient, old short telomere mice 
miRNAs (microRNA) are regulators of messenger RNA stability and translation and 
have been proposed as biomarkers for a variety of diseases and physiological conditions 
(Mendell and Olson, 2012), including aging (Gorospe and Abdelmohsen, 2011; Grillari 
and Grillari-Voglauer, 2010; Weilner et al., 2013). circulating miRNAs may also 
participate in intercellular communications when carried by extracellular vesicles in 
blood as extracellular shuttle RNA (Valadi et al., 2007). Specific nutrients can affect 
circulating miRNA profiles (Ross and Davis, 2011; Ryu et al., 2011), but the intersection 
of Se intake, small RNAs, and aging has not been examined. To maximize confidence, a 
high-throughput platform, TaqMan low density array, was used, and the expression of 
circulating miRNAs was determined by using individual quantitative polymerase chain 
reaction (qPCR) assays (Witwer et al., 2012). To this end, the results from the array had 
profiled over 800 circulating miRNAs in the plasma of Se-deficient and Se-adequate G3 
Terc-/- mice at 12 and 18 months of age. The quality was assessed by individual 
quantitative qPCR assays for spiked cel-miR-39 in samples, and the high throughput data 
were quantile normalized prior to analysis of the datasets.  Of the 131 circulating 
miRNAs that were detectable, the following circulating miRNAs showed the most 
significant changes (p < 0.01): miR-30a, miR-30e, miR-128a, miR-130a, miR-191, miR-
328, miR-375 and miR-1937B increased with dietary Se-deficiency and miR-26b, miR-
29b, miR-30d, miR-138, miR-191, miR-214 and miR-335 increased with age. Thus, 
plasma miR-24, miR-30d, miR-191, miR-375, miR-1937B and miR-let-7 defined the 
unique molecular signature common to both dietary Se deficiency and aging based on the 
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pilot study. To validate the result, the individual qPCR assays of the top ranked miRNAs 
(p < 0.05) were performed, as well as additional miRNAs reported to be aging-associated 
(Hamrick et al., 2010; Park et al., 2012; Takahashi et al., 2012). The results (Figure 4.4A) 
confirmed that plasma miR-130a expression was induced by both dietary Se deficiency 
and aging in G3 Terc-/- mice, miR-21, miR-29a, miR-29c and miR-34a expression were 
induced by dietary Se deficiency but not aging (Figure 4.4B, C, D and E), and miR-30d 
expression was induced by aging but not dietary Se deficiency (Figure 4.4F). Altogether, 
results from the circulating miRNA study suggested that plasma miR-130a was the most 













(A)                                           (B)                                         (C) 
 
(D)                                          (E)                                         (F) 
 
 
Figure 4.4 Real time PCR confirms the expression of age-related, selenium-related 
and age- and selenium-related circulating miRNAs. The potential differential 
expressed miRNAs are reconfirmed by real time PCR. miR-130a is age- and selenium-
related miRNA (A). miR-21, miR-29c, miR-29a and miR-34a are selenium-related 
miRNA (B, C, D and E). miR-30d is age-related miRNA (F). (*, p<0.05; **, p<0.01, 












4.4 Discussion 	  
Mouse models are ideal to test theories of human organismal aging, but one caveat is that 
they have relatively long telomeres, which in human is much shorter. Due to the end-of-
replication problem, telomere length is shortened after each round of cell division, which 
eventually elicits cellular senescence. Available lines of evidence suggest roles of 
nutritional Se and selenoproteins during the aging process (McCann and Ames, 2011), 
but current mouse models of dietary Se or selenoprotein deficiency do not recapitulate 
sufficient and comprehensive features of normal aging. Similarly, Werner syndrome, due 
to inactivating mutations of the WRN gene, develops a spectrum of age-related disorders, 
but knockout of Wrn in mice does not accelerate the onset of the aging phenotypes as 
shown in human Werner syndrome unless they are under a short telomere background 
(Chang et al., 2004). The same is true to recap ataxia telangiectasia in Atm-/- mice (Wong 
et al., 2003). Telomere attrition to critical length is now understood to be able to induce 
replicative senescence and to explain the “Hayflick” limit of culturing primary cells. 
Fibroblasts from individuals with Werner syndrome have accelerated telomere attrition 
and undergo premature senescence that can be rescued by enforced expression of Tert 
(Wyllie et al., 2000), the telomerase catalytic subunit. Interestingly, embryonic 
fibroblasts derived from GPX1-/- mice show senescence-like features in a ROS-dependent 
manner (de Haan et al., 2004). Here, the results had showed that deficiency in dietary 
selenium accelerated the phenotypes of human normal aging in short telomere mice, 
including hair graying, wound healing deficiency, faster telomere attrition, diabetes-like 
symptoms, losing bone integrity and altering the expression of circulating miRNA. 
Altogether, the data has provided the first evidence that dietary Se at nutritional level of 
intake attenuates aging and age-related disorders in mice carrying humanized telomeres.  
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The long-term dietary selenium deficiency in short telomere mice had shown accelerated 
aging and age-related disorders, such as skin abnormality, hair graying, diabetes-like 
phenotype, loss of bone integrity and faster telomere attrition. Interestingly, the similar 
phenotypes of age-related disorders in selenium deficient short telomere mice were also 
reported previously in the other mouse models of selenoprotein deficiency, 
selenocysteine (Sec) tRNA[Ser]Sec gene (Trsp) knockout and isopentenyladenosine-
deficient (i6A-) tRNA[Ser]Sec overexpression. The conditional knockout of Trsp in 
keratinocytes showed skin and hair abnormalities (Sengupta et al., 2010), and in Osteo-
Chondroprogenitor resulted in the defects of bone development (Downey et al., 2009). 
Additionally, the i6A- overexpression mice had increased glucose intolerance and 
diabetes-like phenotypes (Labunskyy et al., 2011). Interestingly, the clinical observed 
mutations in humans on selenocysteine insertion sequence–binding protein 2 (SECISBP2 
or SBP2) impair selenocysteine insertion, which leads to selenoprotein deficiency. The 
patients with SBP2 mutation showed the retardation of bone development, the increase of 
ROS and DNA damage, and faster telomere attrition (Di Cosmo et al., 2009; 
Schoenmakers et al., 2010). With these consistencies of the observed phenotypes in 
genetically modified selenoprotein deficiency and the long-term dietary selenium 
deficiency induced selenoprotein deficiency in short telomere mice, selenoprotein 
deficiency is a potential main factors to accelerate aging and age-related disorders in 
short telomere mice. Noteworthy, Trsp mutated, conditional knockout and complete 
knockout mice have severe survival problems, from shortened lifespan to embryonic 
lethal (Bosl et al., 1997; Carlson et al., 2009; Downey et al., 2009; Sengupta et al., 2010; 
Shrimali et al., 2007), so these animal models with severe selenoprotein deficiency had 
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pointed out the biological functions of selenoproteins may be involved in cell 
differentiation, development and proliferation, which are critical to maintain health span 
and lifespan. However, to study the role of selenoproteins in the pathophysiology of 
normal aging, short telomere mice provides an useful tool to study the biological 
significance of selenoproteins in aging and age-related disorders, because the phenotypic 
changes are gradual but not acute and lethal change, which is not normal aging. On the 
other hand, it is possible to develop intervention for delaying aging and rescuing age-
related disorders by using this dietary selenium deficiency induced accelerated aging in 
short telomere mice.     
Diabetes-like phenotype induced by dietary selenium deficiency may lead to unsuccessful 
aging. Dysfunction on glucose metabolism and developing diabetes are the classic age-
related disorders. Based on the pathophysiology of type 2 diabetes, impaired glucose 
tolerance and insulin resistance are compensated by hyperinsulinemia, and the impaired 
glucose tolerance and insulin resistance will develop later with the failure of β cells in 
pancreas (Rao et al., 2004). The data also suggested the Se-deficient G3 Terc-/- mice had 
the prone to develop diabetes-like symptoms. At 9 month of age, Se-deficient G3 Terc-/- 
mice didn't develop glucose intolerance. Then, the impaired glucose tolerance and insulin 
resistance were developed at 12 moth of age, and the phenotypes were exacerbated at 18 
month of age. In the meantime, the ability on regulating plasma insulin was gradually lost 
in Se-deficient G3 Terc-/- mice. Noteworthy, the average body weights are not discernible 
between Se-deficient and Se-adequate G3 Terc-/- mice before 12 month-old, but there is a 
significant heavier average body weight of Se-deficient G3 Terc-/- mice from 14~18 
month-old. However, the cause of glucose and insulin intolerance was unlikely to be 
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induced by obesity. The plasma insulin data suggested that the glucose intolerance and 
insulin resistance were associated with the limitation on insulin secretion. This may be 
resulted from aging induced β cell dysfunction in pancreas (Gu et al., 2012; Halvorsen et 
al., 2000; Lee et al., 2013). Importantly, the activity of telomerase is still detectable in 
mice but not in human (Liew et al., 2009), so the effect of aging induced β cell 
dysfunction may not appear in wild type mice. As a consequence, Terc-/- mice is a good 
model to study the disorder on glucose metabolism, especially on the aspect of human 
normal aging (Kuhlow et al., 2010). Moreover, the observed significant lower average 
body weight in Se-deficient G3 Terc-/- mice between 21~24 month is another evidence to 
support the possible beta-cell dysfunction, which is one of the typical symptoms of 
diabetes, because the body uses stored fat instead of blood glucose (Durham et al., 2009). 
The data suggested that dietary selenium deficiency may exacerbate the effects of aging, 
which dampening the normal function of β cells and resulting in glucose intolerance, 
insulin resistance and diabetes. 
The identified circulating miRNAs are the potential molecular markers to evaluate the 
molecular age and the risk of age-related disorders. The role of circulating miRNA had 
been identified as a molecular marker and a new species of endocrine signaling 
molecules (Rottiers and Naar, 2012). In the study, the up-regulation of selenium-related 
miRNA (miR-29a/c, miR-21 and miR-34a) and selenium/aging-related miRNA ( miR-
130a ) had been identified. Although there is only miR-130a related to both age and 
selenium, the other selenium-related miRNAs may also participate in the pathway of 
promoting aging. miR-29 had been proposed to involve in senescence (Martinez et al., 
2011; Takahashi et al., 2012), and miR-29 activates p53 to promote aging (Ugalde et al., 
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2011); miR-34 is also related to stabilize p53 for the activation of senescence 
(Yamakuchi and Lowenstein, 2009); miR-21 limited the replicative lifespan, and 
increased endothelial progenitor cells senescence through suppressing high-mobility 
group A2 (Dellago et al., 2013; Zhu et al., 2013b). The emerging evidence indicates that 
the identified selenium-related miRNA in my study may play a critical role in the 
observed accelerated aging in Se-deficient G3 Terc-/- mice. On the other hand, the age-
related disorders had also been reported to be associated with some miRNAs. It had been 
found that the up-regulation of miR-21, miR-29a/c or miR-130a interferes the ability of 
wound healing (Pastar et al., 2012; Wang et al., 2012; Yang et al., 2013 ). On the aspect 
of glucose metabolism,  the up-regulation of miR-34a or miR-29a/c is highly correlated 
to diabetes (Choi et al., 2013; Kong et al., 2011; Locke et al., 2013; Nesca et al., 2013; 
Roggli et al., 2012); miR-130a was highly expressed at hyperglycemia condition 
(Esguerra et al., 2011); miR-21 and miR-34a promoted the pro-inflammatory cytokine 
induced β cell failure (Roggli et al., 2010); the up-regulation of miRN-29a promotes 
impaired glucose tolerance (Bagge et al., 2012). Moreover, miR-21 may induce 
osteoporosis (Yang et al., 2013). The data suggested that the selenium-related and 
selenium and aging-related miRNAs are not only playing as molecular markers for aging 
and age-related disorders, but also provides the link of pathological progressions of aging 
and age-related disorder and dietary selenium.  
The selenium-related miRNAs are associated with the promotion of aging, but they also 
suppress tumorigenesis. Based on openarray and real-time PCR identified miRNA, I 
subjected the identified miRNAs to DIANA miR PATH V. 2.0. for the analysis of 
miRNA targeting pathways (Vlachos et al., 2012). Interestingly, selenium-related 
117	  
	  
miRNAs (miR-34a, miR-29a/c and miR-21) significantly interfere main cancer pathways, 
small cell lung cancer, non-small cell lung cancer, colorectal cancer and pancreatic 
cancer. The major impacts are interfering proliferation, angiogenesis and metastasis. 
Meanwhile, the current evidence suggested miR-29a (Park et al., 2009; Zhu et al., 2013a; 
Zhu et al., 2012), miR-29c (Fan et al., 2013; Wang et al., 2013a; Wang et al., 2013b) and 
miR-34a (Chen et al., 2013; Chiyomaru et al., 2013; Garofalo et al., 2013) have the role 
on anti-tumorigenesis. On the other hand, although miR-21 was proposed to be an 
oncomir to promote tumorigenesis and to be highly expressed in cancer cells (Hong et al., 
2013; Nouraee et al., 2013),  the higher expression level of miR-21 was found to activate 
senescence instead of tumorigenesis in human normal cells (Dellago et al., 2013). Normal 
cells are not like cancer cells, which still retain the functional tumorigenesis barrier, 
oncogene-induced senescence, to prevent the development of malignant cells (Bartkova 
et al., 2006). As a result, Se-deficiency activated miRNAs may reinforce proliferative 
inhibition and senescence to promote aging and also to suppress tumorigenesis. The 
recent report from Kasaikina et al. supported my findings that both selenium deficiency 
and supra-nutritional selenium intake suppressed chemically induced 
hepatocarcinogenesis in FVB mice, and the potential of proliferation was also lower in 
these two conditions (Kasaikina et al., 2013). Thus, even though cancer is considered as 
one of the age-related disorders, the human normal aging model, selenium deprivation in 
Short telomere mice, may not be a good tool for the pathophysiological study of cancer.      
The recent evidence on SELECT trial, GPx1 overexpression and the increasing level of 
Sepp1 points out the potential adverse health effects of supra-nutritional selenium 
consumption, especially the increased risk of diabetes. However, in the study, the results 
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demonstrated that Se-deficient G3 Terc-/- mice showed accelerated aging and age-related 
phenotypes compared with Se-adequate mice. The results shed lights on the importance 
of maintaining adequate dietary selenium is important to prevent selenium deficiency 
induced aging and age-related disorders. Because dietary selenium regulates the 
expression of selenoproteins, which at least have 11 out of 25 selenoproteins related to 
aging (McCann and Ames, 2011), the function of individual selenoprotein on anti-aging 
is required to be identified. Although the known functions of selenoproteins, 
antioxidation, redox signaling and protein folding, are reported to potentially protect 
against aging, there are still some dietary selenium sensitive selenoproteins with 
unknown functions (Kipp et al., 2009; Sunde, 2010), which may involve in the 
prevention of accelerated aging. On the other hand, the new proposed direction that the 
role of selenium or selenoprotein on regulating the expression of miRNA will be the key 











Chapter 5: Conclusion and Prospects 
In this dissertation, cell-based and animal-based approaches have been employed to 
determine the cellular and physiological roles of selenium in replicative senescence and 
organismal aging. The novel finding is that deprivation of selenium at nutritional levels 
of intake accelerates aging and age-related disorders in a mouse model of human normal 
aging, short telomere Terc-/- mouse. Interestingly, previous studies have shown that 
dietary selenium fluctuation alters the expression of selenoproteins to a various degree, 
and SelH is one of the selenoproteins most sensitive to dietary selenium deficiency. By 
employing the SelH stable knockdown human diploid fibroblast, the results demonstrate 
that SelH is critical  for the prevention of early onset of replicative senescence in mortal 
cells through the protection of genome stability. These findings advance the field of 
selenium and aging, and offer several novel prospectives for future recommendations of 
dietary selenium consumption towards healthy aging. 
5.1 The improved recommendation for dietary selenium consumption 
The recommendation of dietary selenium consumption has beenproposed to consider the 
basal level of body selenium status and the form of dietary selenium. Current reports 
based on NPC and SELECT trials provide inconsistent results on selenium being a 
chemoprevention agent. Interestingly, the discrepancy may be attributed to the different 
basal level of body selenium in participants and the form of selenium (Hurst and 
Fairweather-Tait, 2009; Rayman et al., 2009). If the basal body selenium status is high 
prior to entering the trials, individuals do not benefit from selenium supplementation; 
however, in the population with lower body selenium status, selenium supplementation 
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indeed confers cancer chemoprevention. Additionally, the forms of selenium 
supplementation are different in the two clinical trials. Different selenium compounds 
target their specific pathways of metabolism, but the best form of selenium for selenium 
chemoprevention is still little known. Supported by results from animal studies, one thing 
clear is that selenomethione is not an ideal selenium speciation for chemoprevention. 
Moreover, the risk of diabetes after selenomethionine supplementation was found to be 
increased in those who have high basal level of body selenium. Thus, only those with 
sub-optimal body selenium status benefit from supplementation of certain forms of 
selenium. The beneficial effect occurs only within a narrow range surrounding the level 
of nutritional adequacy. 
However, the stage of life cycle should also be considered concerning selenium 
supplementation. In human normal aging, accumulating errors in the body contribute to 
the symptoms of aging and age-related disorders. Optimal body selenium status  
mitigates disadvantages but maximizes advantages regarding healthy aging. Early in life, 
supranutritional selenium is beneficial to secure the expression of fully functional 
selenoproteins for maintenance of physiological functions and cancer prevention by 
activating tumorigenesis barrier in pre-malignant cells. At mid stage, the intake of dietary 
selenium should be cut down to an adequate level. Since genome instability is induced by 
reactive oxygen species and accumulates with age, the oxidative stress generated from 
excessive amount of selenium may exacerbate the aging process. On the other hand, 
previous studies have shown that increased selenium consumption may promote diabetes-
like symptoms. As such, lowering dietary selenium intake to an adequate level may 
maintain functional glucose homeostasis and thus healthy aging. Later in life, dietary 
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selenium deficiency may be beneficial. This is supported by our findings in that selenium 
deficiency activates anti-carcinogenesis miRNAs and SelH deficiency promotes early 
onset of cellular senescence, a tumorigenesis barrier,  in pre-malignant cells. Altogether, 
it is equally important to adjust the recommendation of dietary selenium consumption 
according to the stage of life cycle, body selenium status and selenium speciation, 
towards  optimized health span and lifespan. 
5.2 The role of rDNA damage on replicative senescence and aging 
The nucleolar protein SelH plays a role in the protection against genome instability and 
early onset of replicative senescence. Nucleolus, the region for ribosomal RNA (rRNA) 
transcription, has been proposed to serve as an oxidative stress sensor in the cell 
(Lewinska et al., 2010). When cells experience severe stress, rRNA transcription is 
stopped through JNK2 inactivating transcription factor, TIF-1A (Mayer et al., 2005), 
which allows the cells to overcome the stress. Interestingly, the accumulation of 
extrachromosomal rDNA circles promotes enlargement and fragmentation of the nucleoli 
in aging yeast, which might be further accelerated by rDNA damage (Oberdoerffer and 
Sinclair, 2007; Sinclair and Guarente, 1997). Persistent rDNA damage may constitutively 
trigger DNA damage responses and activate replicative senescence (Kobayashi, 2011). 
Moreover, the formation of heterochromatin in rDNA has been found to be beneficial for 
extending longevity in yeast (Larson et al., 2012). These results point to the possibility 
that rDNA integrity is a critical factor in favor of longevity. Additionally, HR is needed 
for rDNA repair, so the functional HR is required to stabilize rDNA. Furthermore, the 
HR protein, Rad52, has been found to maintain the stability of rDNA copy number 
together with Shu complex (Bernstein et al., 2013). On the other hand, Rad52 facilitates 
122	  
	  
OGG1 for the repair of 8-oxoG, but the helicase activity of Rad52 is blocked by OGG1 
(de Souza-Pinto et al., 2009). As a result, the increased oxidative rDNA damage may 
require BER pathway to fix the lesion but concomitantly suppresses HR on rDNA. 
Ultimately, rDNA instability can promote replicative senescence. As shown in the current 
study, the loss of SelH in the nucleoli may induce intensive DNA damage that dampens 
genome stability, although the hot spot of DNA damage under this condition is still 
unknown. Thus, the critical question is whether SelH can maintain nucleolar integrity in 
the context of  oxidative stress sensing and rDNA stability. To address this question, it is 
of future interest to analyze the hotspots of rDNA damage and to evaluate the efficacy of 
different types of DNA repair pathways in SelH knockdown cells.             
5.3 The control of miRNA expression for optimizing health span and lifespan 
The control of miRNA expression is a potential strategy optimizing health span and 
lifespan. Results from the animal study indicate that circulating miRNAs are useful 
biomarkers and provide "hormone-like" features for long distance regulation. On the 
aspect of optimizing health span and lifespan, it is of future interest to elucidate the 
regulation of the miRNAs expression. miRNAs are powerful regulators. The flexibility of 
sequence specificity enables miRNAs to regulate various signaling pathways. 
Furthermore, the species of miRNAs are too numerous. With these characters in mind, 
miRNAs are indeed powerful yet complicated regulators in the body. Thus, it is required 
to gather further evidence before starting manipulating the expression of specific 
miRNA(s). Reconfirming the role of individual miRNA is necessary to verify the 
biological significance in the body. Based on the differentially expressed miRNAs by 
selenium deficiency and aging, it is possible to study the biological function of specific 
123	  
	  
miRNAs by overexpressing them in cells or in mice. Furthermore, genomic and 
proteomic studies can determine the cross-talk between different miRNAs. The 
expression profiles of miRNAs at different stages of life or genders are important to 
comprehensively realize the roles of miRNAs, which may help to identify the desired end 
point of the intervention. On the other hand, circulating miRNAs are secreted or released 
by various types of tissues and organs. Thus, the increase in circulating miRNAs may 
also indicate the pathophysiological change in specific tissue or organ. To determine the 
main tissue or organ that is affected or secretes the specific miRNA(s) is equally 
important in monitoring the whole expression profile change of circulating miRNAs. 
Furthermore, one should consider to evaluate the pathophysiological condition in the 
body and provide proper ways to optimize the miRNA profile for optimizing health span 
and lifespan.     
Selenium continues to shine in supporting optimal health span and lifespan through 
cancer prevention and other health benefits, regardless of the debating results from the 
two major selenium clinical trials (NPC and SELECT). Currently, the application of 
selenium chemoprevention seems underappreciated; however, re-analysis of the SELECT 
results indicates a role of selenium in cancer prevention. Body selenium status and the 
form of selenium decisively impact on the success of selenium chemoprevention. 
Therefore, the notion of selenium chemoprevention in fact is supported by both NPC and 
SELECT trials. Altogether, exciting lines of  evidence provided in this dissertation have 
provided a new chapter in that selenium is involved in aging and age-related disorders 
through selenium at nutritional level of intake or selenoproteins. At this point, we may 
use a different angle to study the biological functions of selenium and selenoproteins in 
124	  
	  
aging and age-related disorders. Although the clinical trials had established that selenium 
is not a panacea for cancer, little is known about the physiological functions of selenium 
and selenoproteins during organismal aging. Finally, Selenium intervention is not a 
closed case. Herein, the novel approach employing a mouse model of aging carrying 
“humanized” telomere has enabled to demonstrate a physiological role of selenium at 
nutritional levels of intake in the attenuation of aging and age-related disorders, for the 
first time. In conclusion, it is a great opportunity for selenium scientists to jump out the 
original circle, and to explore the new avenues towards understanding selenium functions 
in the biology of aging.        













1. ROS: Reactive oxygen species 
2. BER: Base excision repair 
3. NER: Nucleotide excision repair 
4. MMR: Mismatch repair 
5. HR: Homologous recombination 
6. NHEJ: Non-homologous end-joining 
7. DSB: Double strand break 
8. T-loop: Telomeric-loop 
9. D-loop: Displacement-loop 
10. ATM: Ataxia telangiectasia mutated 
11. ATR: Ataxia telangiectasia mutated rad3 related 
12. DDR: DNA damage response 
13. SSB: Single strand break 
14. HAT: Histone acetyltransferase 
15. HDAC: Histone deacetylase 
16. MAPK: Mitogen-activated protein kinase 
17. DNA-SCARS: DNA segments with chromatin alterations reinforcing senescence  
18. SAHF: Senescence-associated heterochromatin formation 
19. SA-β-gal: Senescence-associated beta-galactosidase 
20. Rb: Retinoblastoma 
21. HMGA: High-mobility group A 
22. SASP: Senescence-associated secretary phenotype 
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23. PARP1: Poly(ADP-ribose) polymerase 1 
24. MRN complex: Mre11-Rad50-NBS1 complex 
25. DRI: Dietary reference intake 
26. RDA: Recommended dietary allowance 
27. NPC: Nutritional prevention of cancer 
28. SELECT: Selenium and vitamin E cancer prevention trial  
29. SBP2: SECIS-binding protein 2 
30. GPx: Glutathione peroxidases 
31. Trx: Thioredoxin 
32. TrxR: Thioredoxin reductases 
33. DIO: Iodothyronine deiodinase 
34. T4: Thyroxine 
35. T3: 3,5,3’-triodothyronine 
36. rT3: Reverse triiodothyronine 
37. Sepp1: Selenoprotein P 
38. apoER2: Apolipoprotein E receptor-2 
39. ER: Endoplasmic reticulum 
40. UGGT: UDP-glucose:glycoprotein glucosyltransferase 
41. SelH: Selenoprotein H 
42. ChIP: Chromatin immunoprecipitation 
43. HSE: Heat shock element 
44. STRE: Stress response element 
45. MRE: Metal response element  
127	  
	  
46. SelN: Selenoprotein N 
47. SelW: Selenoprotein W 
48. MsrB: Methionine sulfoxide reductase B 
49. NAC: N-acetylcysteine 
50. DMSO: Dimethyl sulfoxide 
51. shRNA: Short hairpin RNA 
52. H2DCFDA: 2', 7'-dichlorodihydrofluorescein diacetate  
53. γH2AX: Phospho-H2AX on Ser-139 
54. pATM Ser-1981: Phospho-ATM on Ser-1981 
55. PCNA: Proliferating cell nuclear antigen 
56. GSH: Glutathione 
57. mBCl: Monochlorobimane 
58. qPCR: Quantitative polymerase chain reaction 
59. ip: Intraperitoneal 
60. TMB: 3,3′,5,5′-tetramethylbenzidine 
61. Terc: Telomerase RNA component 
62. Trsp: The gene coded for selenocysteine tRNA 
63. miRNA: MicroRNA 
64. SEC: Selenocysteine 
65. i6A-: Isopentenyladenosine-deficient tRNA[Ser]Sec overexpression 
66. SECIS: Selenocysteine insertion sequence 
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